image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
37d8cacbb73c25560f4f8867604e24cf60191a34e89b2f6e07d06a6bb6e43f1f.png | complex | <table><tr><td colspan="2">Branch and Terminal Node Number and Description</td><td>N</td><td>AT%</td><td>Mean Distance</td></tr><tr><td>Node</td><td>Suburban branch</td><td></td><td></td><td></td></tr><tr><td>1.</td><td>Front porch > 0.83, driveways < 0.83, sidewalks > 0.67</td><td>136</td><td>7 <sup>4,8,9,11,... | <table><tr><td colspan="2">Branch and Terminal Node Number and Description</td><td>N</td><td>AT%</td><td>Mean Distance</td></tr><tr><td>Node</td><td>Suburban branch</td><td></td><td></td><td></td></tr><tr><td>1.</td><td>Front porch > 0.83, driveways < 0.83, sidewalks > 0.67</td><td>136</td><td>7 4,8,9,11,12</td><td>136... | <table><tr><td>7.</td><td>Sidewalk buffer > 0.93, curb cut > 0.91, decorative sidewalks > 0.21, traffic/pedestrian signals < 0.44, zebra crosswalks > 0.03, driveways > 0.83, sidewalks > 0.67</td><td>24</td><td>42 1,2</td><td>739.21 1,4–6,9,11,12</td></tr><tr><td>8.</td><td>Sidewalk buffer < 0.93, curb cut > 0.91, decor... |
02f9d9fc5378fbfb06b05242c19d41e2d203a6a630df24bc40e262cd06f854e7.png | complex | <table><tr><td></td><td></td><td colspan="3">Number (%) of patients</td><td></td></tr><tr><td></td><td></td><td>with PE (N = 107)</td><td>without PE (N = 7175)</td><td>total (N = 7282)</td><td><i>P*</i></td></tr><tr><td>Metabolic syndrome</td><td>yes</td><td>26 (2.7)</td><td>932 (97.3)</td><td>958</td><td>0.001</td></t... | <table><tr><td></td><td></td><td colspan="3">Number (%) of patients</td><td></td></tr><tr><td></td><td></td><td>with PE (N = 107)</td><td>without PE (N = 7175)</td><td>total (N = 7282)</td><td>P*</td></tr><tr><td>Metabolic syndrome</td><td>yes</td><td>26 (2.7)</td><td>932 (97.3)</td><td>958</td><td>0.001</td></tr><tr><... | <table><tr><td></td><td></td><td colspan="3">Number (%) of patients</td><td></td></tr><tr><td></td><td></td><td>with PE (N = 107)</td><td>without PE (N = 7175)</td><td>total (N = 7282)</td><td>P*</td></tr><tr><td></td><td>3</td><td>21 (2.64)</td><td>775 (97.36)</td><td>796</td><td></td></tr><tr><td></td><td>4</td><td>5... |
5d27277dbf27df6dcc0c93bb2183aee3a8f1fbc6ba0baafbe54436abbe8afd47.png | simple | <table><tr><td># Gene ID Gene Description</td></tr><tr><td>AKAP11 A-kinase anchor protein 11 2</td></tr><tr><td>AKR1A1 alcohol dehydrogenase 3</td></tr><tr><td>ATP5O ATP synthase subunit O, mitochondrial precursor 4</td></tr><tr><td>C1orf109 hypothetical protein LOC54955 5</td></tr><tr><td>C2orf29 hypothetical protein ... | <table><tr><td># Gene ID Gene Description</td></tr><tr><td>AKAP11 A-kinase anchor protein 11 2</td></tr><tr><td>AKR1A1 alcohol dehydrogenase 3</td></tr><tr><td>ATP5O ATP synthase subunit O, mitochondrial precursor 4</td></tr><tr><td>C1orf109 hypothetical protein LOC54955 5</td></tr><tr><td>C2orf29 hypothetical protein ... | <table><tr><td># Gene ID Gene Description</td></tr><tr><td>ZNF212 zinc finger protein 212 39</td></tr><tr><td>ZNF683 zinc finger protein 683</td></tr></table> |
663f4502ef940b47563185fb6dd16307b43b895fdb4fe1bbe8e514e6ad2bf6f2.png | simple | <table><tr><td>Part</td><td>Number of sub-parts</td><td>Number of guidance points</td></tr><tr><td>Leadership</td><td>8</td><td>93</td></tr><tr><td>Policy and strategy</td><td>5</td><td>43</td></tr><tr><td>People management</td><td>6</td><td>60</td></tr><tr><td>Resources</td><td>7</td><td>54</td></tr><tr><td>Processes<... | <table><tr><td>Part</td><td>Number of sub-parts</td><td>Number of guidance points</td></tr><tr><td>Leadership</td><td>8</td><td>93</td></tr><tr><td>Policy and strategy</td><td>5</td><td>43</td></tr><tr><td>People management</td><td>6</td><td>60</td></tr><tr><td>Resources</td><td>7</td><td>54</td></tr><tr><td>Processes<... | <table><tr><td>Part</td><td>Number of sub-parts</td><td>Number of guidance points</td></tr><tr><td>People results</td><td>2</td><td>36</td></tr><tr><td>Contractor results</td><td>2</td><td>33</td></tr><tr><td>Key performance results</td><td>2</td><td>19</td></tr><tr><td>Total</td><td>38</td><td>410</td></tr></table> |
5a89a5c42def5a50cd06cdf505a4522ee073a81ba0a4e7c479dad51428f4c7e9.png | complex | <table><tr><td>Variable</td><td></td><td>N (92,082)</td><td>% (100.0)</td></tr><tr><td rowspan="5">Age (years)</td><td>30–39</td><td>20,069</td><td>21.8</td></tr><tr><td>40–49</td><td>23,377</td><td>25.4</td></tr><tr><td>50–59</td><td>19,776</td><td>21.5</td></tr><tr><td>60–69</td><td>15,954</td... | <table><tr><td>Variable</td><td></td><td>N (92,082)</td><td>% (100.0)</td></tr><tr><td rowspan="5">Age (years)</td><td>30–39</td><td>20,069</td><td>21.8</td></tr><tr><td>40–49</td><td>23,377</td><td>25.4</td></tr><tr><td>50–59</td><td>19,776</td><td>21.5</td></tr><tr><td>60–69</td><td>15,954</td><td>17.3</td></tr><tr><... | <table><tr><td>Variable</td><td></td><td>N (92,082)</td><td>% (100.0)</td></tr><tr><td rowspan="2">gnosed hypertension</td><td>s</td><td>40</td><td>0.7</td></tr><tr><td>No</td><td>72,985</td><td>79.3</td></tr><tr><td rowspan="2">Physician-diagnosed diabetes</td><td>Yes</td><td>7991</td><td>8.7</td></tr><tr><td>No</td><... |
ce4236710e887a3795b3f142db5a8d812edb50983e2ebe08549d7b6f0f825734.png | simple | <table><tr><td></td><td>Nutridrink</td><td>Impact</td><td>Return to Nutridrink</td><td><i>p</i></td></tr><tr><td>Body weight (kg)</td><td>57 ± 5.8</td><td>57 ± 5.9</td><td>58 ± 5.8</td><td>NS</td></tr><tr><td>Systolic BP (mmHg)</td><td>115 ± 11</td><td>110 ± 7</td><td>117 ± 11</td><td>0.01... | <table><tr><td></td><td>Nutridrink</td><td>Impact</td></tr><tr><td>Body weight (kg)</td><td>57 ± 5.8</td><td>57 ± 5.9</td></tr><tr><td>Systolic BP (mmHg)</td><td>115 ± 11</td><td>110 ± 7</td></tr><tr><td>Diastolic BP (mmHg)</td><td>69 ± 9</td><td>64 ± 8</td></tr><tr><td>Heart rate (pulse/min)</td><td>88 ± 15</td><td>77... | <table><tr><td>Return to Nutridrink</td><td>p</td></tr><tr><td>58 ± 5.8</td><td>NS</td></tr><tr><td>117 ± 11</td><td>0.012</td></tr><tr><td>69 ± 9</td><td>0.03</td></tr><tr><td>80 ± 14</td><td>0.002</td></tr><tr><td>19 ± 1.6</td><td>NS</td></tr></table> |
2498a02953e3717965f69649dbd213a807521790906f533aedf17c6671b717a6.png | complex | <table><tr><td rowspan="2">Variable</td><td>Overall</td><td>Girls</td><td>Boys</td><td><i>p</i>-Value</td></tr><tr><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td><i>N</i> (%)</td><td>(Chi-Square Test)</td></tr><tr><td>Physical activity level</td><td></td><td></td><td></td><td></td></tr><tr><td> Sedentary</td><td>98 (36.... | <table><tr><td rowspan="2">Variable</td><td>Overall</td><td>Girls</td><td>Boys</td></tr><tr><td>N (%)</td><td>N (%)</td><td>N (%)</td></tr><tr><td>Physical activity level</td><td></td><td></td><td></td></tr><tr><td>Sedentary</td><td>98 (36.8)</td><td>48 (41.0)</td><td>50 (33.6)</td></tr><tr><td>Moderate</td><td>60 (22.... | <table><tr><td>p-Value</td></tr><tr><td>(Chi-Square Test)</td></tr><tr><td></td></tr><tr><td rowspan="4">0.252</td></tr><tr></tr><tr></tr><tr></tr><tr><td></td></tr><tr><td rowspan="5">0.019 *</td></tr><tr></tr><tr></tr><tr></tr><tr></tr><tr><td></td></tr><tr><td rowspan="4">0.712</td></tr><tr></tr><tr></tr><tr></tr><t... |
4116cbc1cbb97952c5fa484edb9cf0a53a03ca916a6f2c65899fe51dbc6d0d1c.png | simple | <table><tr><td>Characteristics</td><td>n<sup>£</sup></td><td>Mean</td><td>SD</td><td>Median</td><td>p-value</td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td><td></td><td>0.7011*</td></tr><tr><td>White</td><td>1756</td><td>110.7</td><td>56</td><td>106.9</td><td></td></tr><tr><td>Non-white</td><td>433</td><... | <table><tr><td>Characteristics</td><td>n£</td><td>Mean</td><td>SD</td><td>Median</td><td>p-value</td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td><td></td><td>0.7011*</td></tr><tr><td>White</td><td>1756</td><td>110.7</td><td>56</td><td>106.9</td><td></td></tr><tr><td>Non-white</td><td>433</td><td>109.3</td><td... | <table><tr><td>Gestational age (US)</td><td></td><td></td><td></td><td></td><td>< 0.0001**</td></tr><tr><td>13</td><td>18</td><td>18.3</td><td>6.9</td><td>18.7</td><td></td></tr><tr><td>14</td><td>43</td><td>23.3</td><td>7.5</td><td>23.4</td><td></td></tr><tr><td>15</td><td>59</td><td>27.2</td><td>8.1</td><td>26.5</td>... |
0cfbb1128c0d11c4228565b90fc8e5cd820837c3a82461feb0150c9194a86eed.png | simple | <table><tr><td>Independent variables </td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>Health-related risk factors </td><td> </td><td> </td><td> </td></tr><tr><td> Medical conditions (index)</td><td>−0.134<sup>***</sup></td><td>−0.052<sup>***</sup></td><td>−0.036<sup>*</sup></td></tr><... | <table><tr><td>Independent variables</td><td>Model 1</td><td>Model 2</td><td>Model 3</td></tr><tr><td>Health-related risk factors</td><td></td><td></td><td></td></tr><tr><td>Medical conditions (index)</td><td>−0.134***</td><td>−0.052***</td><td>−0.036*</td></tr></table> | <table><tr><td>Mobility difficulties (index)</td><td>−0.273***</td><td>−0.115***</td><td>−0.079***</td></tr><tr><td>Activity limitations (index)</td><td>−0.504***</td><td>−0.196***</td><td>−0.168***</td></tr><tr><td>Sociodemographic variables</td><td></td><td></td><td></td></tr><tr><td>Age (cont.)</td><td></td><td></td... |
7e4f19c69f0c9d6c0553125eeb3ff5dfe8abe98a22d45c84cc82894331384840.png | simple | <table><tr><td> </td><td> </td><td>β</td><td>95% CI</td><td>p value</td></tr><tr><td>Intercept</td><td> </td><td>-4.64</td><td>-8.93; -0.35</td><td> </td></tr><tr><td>Group (Reference: controls)</td><td>NSCLC</td><td>1.63</td><td>0.75; 2.51</td><td>0.0004</td></tr><tr><td>Gender (Reference: male)</td><td>Female</t... | <table><tr><td></td><td></td><td>β</td><td>95% CI</td><td>p value</td></tr></table> | <table><tr><td>Intercept</td><td></td><td>-4.64</td><td>-8.93; -0.35</td><td></td></tr><tr><td>Group (Reference: controls)</td><td>NSCLC</td><td>1.63</td><td>0.75; 2.51</td><td>0.0004</td></tr><tr><td>Gender (Reference: male)</td><td>Female</td><td>0.22</td><td>-0.66; 1.10</td><td>0.6210</td></tr><tr><td>Age</td><td>[1... |
6471c54377e01fec4851589384c90e5906a1286843c84f13feadbfa38306a274.png | complex | <table><tr><td>Test Type</td><td colspan="2">5-Option Version (n = 25)</td><td colspan="2">2-Option Version (n = 37)</td></tr><tr><td></td><td>Without OPC</td><td>With OPC*</td><td>Without OPC</td><td>With OPC**</td></tr><tr><td>FOBT</td><td>21%</td><td>17%</td><td>32%</td><td>54%</td></tr><tr><td>Sigmoidoscopy</td><td... | <table><tr><td>Test Type</td><td colspan="2">5-Option Version (n = 25)</td><td>2-Option Version (n = 37)</td></tr><tr><td></td><td>Without OPC</td><td>With OPC*</td><td>Without OPC</td></tr><tr><td>FOBT</td><td>21%</td><td>17%</td><td>32%</td></tr><tr><td>Sigmoidoscopy</td><td>4%</td><td>8%</td><td>-</td></tr><tr><td>F... | <table><tr><td>2-Option Version (n = 37)</td></tr><tr><td>With OPC**</td></tr><tr><td>54%</td></tr><tr><td>-</td></tr><tr><td>-</td></tr><tr><td>41%</td></tr><tr><td>-</td></tr><tr><td>5%</td></tr></table> |
749c2383854fa486ed84ba2a24a7ea56c17764ddf9e53fe7f48d94e48d768969.png | complex | <table><tr><td rowspan="2">Parameter</td><td colspan="2">GM (CV %)<sup>a</sup></td><td colspan="2">GMR (90% CI)<sup>a</sup></td></tr><tr><td>Pre-moringa</td><td>Post-moringa</td><td>Post/Pre</td><td>P</td></tr><tr><td>AUC<sub>0–12h</sub> (h*μg/mL)</td><td>94.17 (25.24)</td><td>100.44 (27.65)</td><td>1.07 (1.... | <table><tr><td rowspan="2">Parameter</td><td>GM (CV %)a</td></tr><tr><td>Pre-moringa</td></tr><tr><td>AUC0–12h (h*μg/mL)</td><td>94.17 (25.24)</td></tr><tr><td>C12h (μg/mL)</td><td>7.30 (25.85)</td></tr><tr><td>Cmax,ss (μg/mL)</td><td>9.92 (26.93)</td></tr></table> | <table><tr><td>GM (CV %)a</td><td colspan="2">GMR (90% CI)a</td></tr><tr><td>Post-moringa</td><td>Post/Pre</td><td>P</td></tr><tr><td>100.44 (27.65)</td><td>1.07 (1.00–1.14)</td><td>0.131</td></tr><tr><td>7.55 (28.56)</td><td>1.03 (0.92–1.16)</td><td>0.702</td></tr><tr><td>10.57 (29.62)</td><td>1.06 (0.98–1.16)</td><td... |
87bbafb3dfa85ac171b69aa1149c1c17bb3258f81f571c92f9f6138b1e6a7b26.png | complex | <table><tr><td rowspan="2"> </td><td>Overall</td><td colspan="2">Chronic kidney disease at baseline</td><td rowspan="2"><i>p</i> values</td></tr><tr><td>(<i>n</i> = 162)</td><td>Present (<i>n</i> = 25)</td><td>Absent (<i>n</i> = 137)</td></tr><tr><td>Male sex (<i>n</i>, %)</td><td>89, 55</td><td>12, 48</td><td>77, 56</... | <table><tr><td rowspan="2"></td><td>Overall</td><td colspan="2">Chronic kidney disease at baseline</td><td rowspan="2">p values</td></tr><tr><td>(n = 162)</td><td>Present (n = 25)</td><td>Absent (n = 137)</td></tr><tr><td>Male sex (n, %)</td><td>89, 55</td><td>12, 48</td><td>77, 56</td><td>0.45</td></tr><tr><td>Smokers... | <table><tr><td rowspan="2"></td><td>Overall</td><td colspan="2">Chronic kidney disease at baseline</td><td rowspan="2">p values</td></tr><tr><td>(n = 162)</td><td>Present (n = 25)</td><td>Absent (n = 137)</td></tr><tr><td>, %)</td><td>3</td><td>48</td><td>30</td><td>08</td></tr></table> |
eb0fec0d298d5fd43507153ecf98b1fd1ca07c70cef92bc01ce3c3c0e850cbff.png | simple | <table><tr><td>Hierarchy Depth</td><td>PPStream</td><td>PPTV</td><td>QQLive</td><td>PPfilm</td><td>UUSee</td><td>All</td></tr><tr><td>1</td><td>19.12%</td><td>3.20%</td><td>15.95%</td><td>8.34%</td><td>3.25%</td><td>14.72%</td></tr><tr><td>2</td><td>80.87%</td><td>44.69%</td><td>9.34%</td><td>43.35%</td><td>85.64%</td>... | <table><tr><td>Hierarchy </td><td>PPStre</td><td>P</td><td></td><td></td><td>UUS</td><td>All</td></tr></table> | <table><tr><td>Depth</td><td>am</td><td>PTV</td><td>QQLive</td><td>PPfilm</td><td>ee</td><td></td></tr><tr><td>1</td><td>19.12%</td><td>3.20%</td><td>15.95%</td><td>8.34%</td><td>3.25%</td><td>14.72%</td></tr><tr><td>2</td><td>80.87%</td><td>44.69%</td><td>9.34%</td><td>43.35%</td><td>85.64%</td><td>50.76%</td></tr><tr... |
05c5f9d87b014294bbd3514d7ce6736f27ea8616d6b8830bc356c316527d48b7.png | complex | <table><tr><td rowspan="2">Time from onset of illness </td><td rowspan="2">Signs/symptoms</td><td rowspan="2">Drug exposure </td><td colspan="5">Laboratory values</td></tr><tr><td>ALT</td><td>ALP</td><td>Total bilirubin</td><td>Direct bilirubin</td><td>Misc.</td></tr><tr><td>−5</td><td>Sore throat</td><td>Amoxici... | <table><tr><td rowspan="2">Time from onset of illness</td><td rowspan="2">Signs/symptoms</td><td rowspan="2">Drug exposure</td><td colspan="2">Laboratory values</td></tr><tr><td>ALT</td><td>ALP</td></tr><tr><td>−5</td><td>Sore throat</td><td>Amoxicillin started</td><td></td><td></td></tr><tr><td>0</td><td>Fever, anorex... | <table><tr><td colspan="3">Laboratory values</td></tr><tr><td>Total bilirubin</td><td>Direct bilirubin</td><td>Misc.</td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td>3.0</td><td>2.7</td><td></td></tr><tr><td>... |
3bdfcfeaa81caae9b2b951164302a3b2746c092b81fcdccae3f0ab94d39f469c.png | simple | <table><tr><td>Inclusion criteria</td><td>Exclusion criteria</td></tr><tr><td>Original research articles referring to noninvasive modalities or minimally invasive techniques to accelerate orthodontic tooth movementAnimal studies</td><td>Randomized clinical trialsArticles dealing with highly invasive proceduresArticles ... | <table><tr><td>Inclusion criteria</td></tr><tr><td>Original research articles referring to noninvasive modalities or minimally invasive techniques to accelerate orthodontic tooth movementAnimal studies</td></tr></table> | <table><tr><td>Exclusion criteria</td></tr><tr><td>Randomized clinical trialsArticles dealing with highly invasive proceduresArticles referring to use of biochemical or drugs to accelerate tooth movementMicroimplants or frictionless brackets as a modality to reduce treatment duration Reviews, interviews, and discussion... |
5130f090a192def49d78284176a0f51004408773afa9cda306687f054fcd343f.png | simple | <table><tr><td></td><td>GP*</td><td>Combinations*</td></tr><tr><td></td><td>OR (95% CI)<sup>†</sup></td><td>OR (95% CI)<sup>†</sup></td></tr><tr><td>Age</td><td>1.00 (0.99-1.02)</td><td>1.00 (0.98-1.02)</td></tr><tr><td>Man</td><td>1.00</td><td>1.00</td></tr><tr><td>Woman</td><td>1.24 (0.84-1.85)</td><td>1.... | <table><tr><td></td><td>GP*</td><td>Combinations*</td></tr><tr><td></td><td>OR (95% CI)†</td><td>OR (95% CI)†</td></tr><tr><td>Age</td><td>1.00 (0.99-1.02)</td><td>1.00 (0.98-1.02)</td></tr><tr><td>Man</td><td>1.00</td><td>1.00</td></tr></table> | <table><tr><td>Woman</td><td>1.24 (0.84-1.85)</td><td>1.17 (0.83-1.65)</td></tr><tr><td>Normal weight (BMI < 25 kg/m2)</td><td>1.00</td><td>1.00</td></tr><tr><td>Overweight (BMI 25-29.99 kg/m2)</td><td>1.35 (0.81-2.26)</td><td>1.71 (1.09-2.68)</td></tr><tr><td>Obese (BMI ≥ 30 kg/m2)</td><td>1.72 (1.00-2.93)</td><td>1.6... |
29773f3ebdf2e68650a53d3ab35377a03a1b0e3cef305a6e22fa0a47673ad54c.png | complex | <table><tr><td rowspan="2">Area</td><td rowspan="2">Parameter estimate (SE)</td><td rowspan="2"><i>t</i>‐Value (<i>P</i>‐value) for parameter difference from zero</td><td colspan="5"><i>t</i>‐Values (<i>P</i>‐values) for differences of least squares means</td></tr><tr><td>Garbage</td><td>Light</... | <table><tr><td rowspan="2">Area</td><td rowspan="2">Parameter estimate (SE)</td><td rowspan="2">t‐Value (P‐value) for parameter difference from zero</td><td colspan="5">t‐Values (P‐values) for differences of least squares means</td></tr><tr><td>Garbage</td><td>Light</td><td>Lawn</td><td>Other modified</td><td>Natural</... | <table><tr><td rowspan="2">Area</td><td rowspan="2">Parameter estimate (SE)</td><td rowspan="2">t‐Value (P‐value) for parameter difference from zero</td><td colspan="5">t‐Values (P‐values) for differences of least squares means</td></tr><tr><td>Garbage</td><td>Light</td><td>Lawn</td><td>Other modified</td><td>Natural</... |
35ad47d8f26aba7b94956169dc60f9b995ee7e5c90087a56afcae4a214be9a89.png | simple | <table><tr><td>Sample Name</td><td>Raw Reads</td><td>Clean Reads</td><td>Clean Bases</td><td>Total Mapped</td><td>Error Rate (%)</td><td>Q20 (%)</td><td>Q30 (%)</td><td>GC Content (%)</td></tr><tr><td>O<sub>2</sub>-treated_1</td><td>12,984,364</td><td>12,920,255</td><td>0.65 G</td><td>12,360,505 (95.67%)</td><td>0.01</... | <table><tr><td>Sample Name</td><td>Raw Reads</td><td>Clean Reads</td><td>Clean Bases</td><td>Total Mapped</td><td>Error Rate (%)</td><td>Q20 (%)</td><td>Q30 (%)</td><td>GC Content (%)</td></tr><tr><td>O2-treated_1</td><td>12,984,364</td><td>12,920,255</td><td>0.65 G</td><td>12,360,505 (95.67%)</td><td>0.01</td><td>97.9... | <table><tr><td>HCl-treated_2</td><td>13,595,227</td><td>13,514,169</td><td>0.68 G</td><td>12,993,548 (96.15%)</td><td>0.01</td><td>98.64</td><td>95.87</td><td>45.03</td></tr><tr><td>Non-treated_1</td><td>12,361,440</td><td>12,313,326</td><td>0.62 G</td><td>11,827,559 (96.05%)</td><td>0.01</td><td>97.91</td><td>94.12</t... |
363d976632a8a3944b3e7d520bd40ea1df759832410db6e6f39b0b4b2571935d.png | simple | <table><tr><td>Locus</td><td>Primer sequences (5<sup>′</sup>–3<sup>′</sup>)</td><td>Primer sequences (5<sup>′</sup>–3<sup>′</sup>)</td></tr><tr><td>b50</td><td>F: AACAATCCAGGAGTGGCAATC</td><td>R: ACAAGCGAAGATCGTCTCATC</td></tr><tr><td>b35</td><td>F: CGTTCAGTCACCAGCAAGG</td><td>R: GAG... | <table><tr><td>Locus</td><td>Primer sequences (5′–3′)</td></tr><tr><td>b50</td><td>F: AACAATCCAGGAGTGGCAATC</td></tr><tr><td>b35</td><td>F: CGTTCAGTCACCAGCAAGG</td></tr><tr><td>b38</td><td>F: TAATCCCTCAATGGCTCTTTTC</td></tr><tr><td>b40</td><td>F:TGTATAGAACTGAGTAAATGATTG</td></tr><tr><td>b43</td><td>F: CGAGCCTTCTTCTTCTT... | <table><tr><td>Primer sequences (5′–3′)</td></tr><tr><td>R: ACAAGCGAAGATCGTCTCATC</td></tr><tr><td>R: GAGGGAAGCAGGGAGAGC</td></tr><tr><td>R: GAGAAGGATACGAATTGACAGG</td></tr><tr><td>R: CAACTTTCTTAAACCACTTTCG</td></tr><tr><td>R: GCAAGCAATACGGACAGTAGG</td></tr><tr><td>R: ACTGTAACAATCAAGAAGAAACC</td></tr><tr><td>R: TCTCATC... |
63f89033a552f02f8685503067f548596aaa8a96e04c7c9cc45b08a6cbb21777.png | complex | <table><tr><td rowspan="2">Phases</td><td rowspan="2">Contacted</td><td rowspan="2">Screening1<sup>a</sup></td><td rowspan="2">Screening2<sup>b</sup></td><td rowspan="2">Screening3<sup>c</sup></td><td colspan="2">Successfully recruited</td></tr><tr><td>IG</td><td>CG</td></tr><tr><td>Run-in</td><td>214</td><td>184 (86)<... | <table><tr><td rowspan="2">Phases</td><td rowspan="2">Contacted</td><td rowspan="2">Screening1a</td><td rowspan="2">Screening2b</td><td rowspan="2">Screening3c</td><td colspan="2">Successfully recruited</td></tr><tr><td>IG</td><td>CG</td></tr><tr><td>Run-in</td><td>214</td><td>184 (86)</td><td>106 (50)</td><td>109 (51)... | <table><tr><td>TOTAL</td><td>702</td><td>562 (80)</td><td>412 (59)</td><td>409 (58)</td><td>190 (27)</td><td>190 (27)</td></tr></table> |
7d49e2268b26478bfed42bd398b7a0c5041b1d68e4a963f6a29c309beba62d94.png | complex | <table><tr><td colspan="3">Study characteristics</td><td colspan="2">WBC</td><td colspan="2">Monocytes</td><td colspan="2">Neutrophils</td><td colspan="2">Lymphocytes</td><td colspan="2">Neutrophil to lymphocyte ratio</td><td>Reference</td></tr><tr><td>Population</td><td>FU</td><td>Size (<i>n</i>)</td><td>Risk [95% CI]... | <table><tr><td colspan="3">Study characteristics</td><td colspan="2">WBC</td><td colspan="2">Monocytes</td><td colspan="2">Neutrophils</td><td colspan="2">Lymphocytes</td></tr><tr><td>Population</td><td>FU</td><td>Size (n)</td><td>Risk [95% CI]</td><td>p</td><td>Risk [95% CI]</td><td>p</td><td>Risk [95% CI]</td><td>p</... | <table><tr><td colspan="2">Neutrophil to lymphocyte ratio</td><td>Reference</td></tr><tr><td>Risk [95% CI]</td><td>p</td><td></td></tr><tr><td></td><td></td><td>(27)</td></tr><tr><td>5.6 [1.6–19.8]</td><td>**</td><td>(40)</td></tr><tr><td></td><td></td><td>(29)</td></tr><tr><td></td><td></td><td>(41)</td></tr><tr><td><... |
6488f2e501a3a1df9bc01288356d66ce53f0f5712ea09ff13365ccffb7c848a8.png | simple | <table><tr><td>Second-level category</td><td><i>n</i> (%)</td></tr><tr><td>b140 attention functions</td><td>149 (85)</td></tr><tr><td>b130 energy and drive functions</td><td>127 (73)</td></tr><tr><td>b147 psychomotor functions</td><td>124 (71)</td></tr><tr><td>b760 control of voluntary movement functions</td><td>114 (6... | <table><tr><td>Second-level category</td><td>n (%)</td></tr><tr><td>b140 attention functions</td><td>149 (85)</td></tr><tr><td>b130 energy and drive functions</td><td>127 (73)</td></tr><tr><td>b147 psychomotor functions</td><td>124 (71)</td></tr></table> | <table><tr><td>b760 control of voluntary movement functions</td><td>114 (65)</td></tr><tr><td>b164 higher-level cognitive functions</td><td>106 (61)</td></tr><tr><td>b152 emotional functions</td><td>90 (51)</td></tr><tr><td>b126 temperament and personality functions</td><td>64 (37)</td></tr><tr><td>b125 dispositions an... |
51ea889d2dca48d108499386ab8c663f675f9afc919ae406eee77d8c8b2dd48e.png | simple | <table><tr><td></td><td>Total</td><td>Asp299Asp</td><td>Asp299Gly</td><td><i>P</i></td></tr><tr><td>n (%)</td><td>138</td><td>125 (90.6)</td><td>13 (9.4)</td><td></td></tr><tr><td> Oro-Hypopharyngeal SCC; n (%)</td><td>37</td><td>34 (91.9)</td><td>3 (8.1)</td><td>0.76</td></tr><tr><td> Laryngeal SCC; n (%)</td><td>101<... | <table><tr><td></td><td>Total</td><td>Asp299Asp</td><td>Asp299Gly</td><td>P</td></tr><tr><td>n (%)</td><td>138</td><td>125 (90.6)</td><td>13 (9.4)</td><td></td></tr><tr><td>Oro-Hypopharyngeal SCC; n (%)</td><td>37</td><td>34 (91.9)</td><td>3 (8.1)</td><td>0.76</td></tr><tr><td>Laryngeal SCC; n (%)</td><td>101</td><td>9... | <table><tr><td>1; n (%)</td><td>9</td><td>7 (5.6)</td><td>2 (15.4)</td></tr><tr><td>2; n (%)</td><td>96</td><td>87 (69.6)</td><td>9 (69.2)</td></tr><tr><td>3-4; n (%)</td><td>25</td><td>23 (18.4)</td><td>2 (15.4)</td></tr></table> |
b99ce6eb8705264f99054dfcf90aa2d3c39777514f947d785aa075fd882c9f97.png | simple | <table><tr><td></td><td>Total number</td><td>Gleason grade group 1</td><td>Gleason grade group 2</td><td>Gleason grade group 3</td><td>Gleason grade group 4</td><td>Gleason grade group 5</td></tr><tr><td>N° of primary tumors</td><td>60</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td></tr><tr><td>N°... | <table><tr><td></td><td>Total number</td><td>Gleason grade group 1</td><td>Gleason grade group 2</td><td>Gleason grade group 3</td><td>Gleason grade group 4</td><td>Gleason grade group 5</td></tr></table> | <table><tr><td>N° of primary tumors</td><td>60</td><td>12</td><td>12</td><td>12</td><td>12</td><td>12</td></tr><tr><td>N° of CD44v8-10</td><td>24</td><td>3</td><td>3</td><td>5</td><td>6</td><td>5</td></tr><tr><td>% positive tumors</td><td>40%</td><td>25%</td><td>25%</td><td>42%</td><td>50%</td><td>42%</td></tr></table> |
bd7742a7d3779064adfc14e4b139e7b569f157475e12a8cea08d6b89e8a0f695.png | complex | <table><tr><td> </td><td colspan="3">Boys</td><td colspan="3">Girls</td></tr><tr><td> </td><td>Verbal abuse</td><td>Threat of violence</td><td>Physical assault</td><td>Verbal abuse</td><td>Threat of violence</td><td>Physical assault</td></tr><tr><td>Verbal abuse</td><td>1.00</td><td> </td><td> </td><td>1.00</td><td> </... | <table><tr><td></td><td colspan="3">Boys</td><td colspan="3">Girls</td></tr></table> | <table><tr><td></td><td>Verbal abuse</td><td>Threat of violence</td><td>Physical assault</td><td>Verbal abuse</td><td>Threat of violence</td><td>Physical assault</td></tr><tr><td>Verbal abuse</td><td>1.00</td><td></td><td></td><td>1.00</td><td></td><td></td></tr><tr><td>Threat of violence</td><td>0.35*</td><td>1.00</td... |
b7ea718770646b4932e6307cfac20073a8426f7429352e9e8e925cdc676b32dd.png | complex | <table><tr><td> </td><td colspan="2">Clinical setting</td></tr><tr><td>Barrier</td><td>HTN & eGFR ≥ 60 (%)</td><td>HTN & eGFR < 60 (%)</td></tr><tr><td>No impact on management</td><td>37</td><td>24</td></tr><tr><td>Limited time/more urgent patient issues</td><td>25</td><td>20</td></tr><tr><td>Not recom... | <table><tr><td></td><td>Clinical setting</td></tr><tr><td>Barrier</td><td>HTN & eGFR ≥ 60 (%)</td></tr><tr><td>No impact on management</td><td>37</td></tr><tr><td>Limited time/more urgent patient issues</td><td>25</td></tr><tr><td>Not recommended by guidelines</td><td>25</td></tr><tr><td>Cost</td><td>13</td></tr><tr><t... | <table><tr><td>Clinical setting</td></tr><tr><td>HTN & eGFR < 60 (%)</td></tr><tr><td>24</td></tr><tr><td>20</td></tr><tr><td>11</td></tr><tr><td>9</td></tr><tr><td>5</td></tr></table> |
cf6e040c25d10e41e34272078e3617d92b761d5282e65a24591c952a9459fd99.png | complex | <table><tr><td rowspan="2">Progression to PID</td><td rowspan="2">Fraction progressing, % (95% CI)<sup>*</sup></td><td colspan="2">Cumulative incidence of PID after one year, % (95% CI)<sup>†</sup></td><td rowspan="2">Akaike’s Information Criterion<sup>‡</sup></td></tr><tr><td>Control group</td><td>In... | <table><tr><td rowspan="2">Progression to PID</td><td rowspan="2">Fraction progressing, % (95% CI)*</td><td colspan="2">Cumulative incidence of PID after one year, % (95% CI)†</td><td rowspan="2">Akaike’s Information Criterion‡</td></tr><tr><td>Control group</td><td>Intervention group</td></tr><tr><td>Data</td><td></td... | <table><tr><td></td><td></td><td>9 (1.2 to 2.9)</td><td> (0.7 to 2.1)</td><td></td></tr><tr><td>Model</td><td></td><td></td><td></td><td></td></tr><tr><td>Immediate progression</td><td>8.3 (5.7 to 11.0)</td><td>1.6 (1.1 to 2.1)</td><td>1.6 (1.1 to 2.1)</td><td>13.3</td></tr><tr><td>Constant progression</td><td>9.9 (6.8... |
f4f55eff858fa711c198b313af0ae3362bc9cdf86bf1b148de7bce1b36d65184.png | simple | <table><tr><td>Fc <i>γ</i> IIA genotype</td><td>Mild (<8)</td><td>Moderate (8–18)</td><td>Severe (>18)</td></tr><tr><td>R131/R131 (<i>n</i> = 16)</td><td>2</td><td>4</td><td>10</td></tr><tr><td>R131/H131 (<i>n</i> = 54)</td><td>10</td><td>26</td><td>18</td></tr><tr><td>H131/H131 (<i>n</i> = 10)</td><td... | <table><tr><td>Fc γ IIA genotype</td><td>Mild (<8)</td><td>Moderate (8–18)</td><td>Severe (>18)</td></tr></table> | <table><tr><td>R131/R131 (n = 16)</td><td>2</td><td>4</td><td>10</td></tr><tr><td>R131/H131 (n = 54)</td><td>10</td><td>26</td><td>18</td></tr><tr><td>H131/H131 (n = 10)</td><td>0</td><td>10</td><td>0</td></tr><tr><td>Total (n = 80)</td><td>12 (15%)</td><td>40 (50%)</td><td>28 (35%)</td></tr></table> |
75342cb85126a050ee72e37de48b78c49741fff505d659dc45652ff6510d303d.png | simple | <table><tr><td> </td><td>Pharmacologic intervention title: ‘Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomized placebo-controlled trial’ [28]</td><td>Non-pharmacologic intervention title: ‘Treatment of childhood obesity by retraining eating behaviour: ... | <table><tr><td></td><td>Pharmacologic intervention title: ‘Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomized placebo-controlled trial’ [28]</td><td>Non-pharmacologic intervention title: ‘Treatment of childhood obesity by retraining eating behaviour: randomized controll... | <table><tr><td>Active ingredients</td><td>Vitamins C and E</td><td>Not reported</td></tr><tr><td>Comparator</td><td>Placebo</td><td>Not reported</td></tr><tr><td>Health condition</td><td>Pre-eclampsia</td><td>Obesity</td></tr><tr><td>Eligibility criteria</td><td>Women with type 1 diabetes</td><td>Children</td></tr><tr>... |
5d2ad6dabb42780197282912c158daacfc5ea514ba920ef57f91090e53add307.png | simple | <table><tr><td>Item</td><td>N-free</td><td>Soybean meal</td><td>Rapeseed meal</td><td>Canola meal</td></tr><tr><td>Ingredients (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Corn starch</td><td>56.50</td><td>44.79</td><td>32.34</td><td>37.94</td></tr><tr><td>Soybean meal (44 %)</td><td>-</td><td>52.24</td><td... | <table><tr><td>Item</td><td>N-free</td><td>Soybean meal</td><td>Rapeseed meal</td><td>Canola meal</td></tr><tr><td>Ingredients (%)</td><td></td><td></td><td></td><td></td></tr></table> | <table><tr><td>Corn starch</td><td>56.50</td><td>44.79</td><td>32.34</td><td>37.94</td></tr><tr><td>Soybean meal (44 %)</td><td>-</td><td>52.24</td><td>-</td><td>-</td></tr><tr><td>Rapeseed meal (35 %)</td><td>-</td><td>-</td><td>65.57</td><td>-</td></tr><tr><td>Canola meal (38 %)</td><td>-</td><td>-</td><td>-</td><td>... |
df6da30263d07dcf79de289521b727b6ee72bde7e7a19ca977e051a820cb180b.png | simple | <table><tr><td>Matrix Mechanical Characteristics that Impact Cell or Tissue Function</td></tr><tr><td>• Pore size and morphology (Chan et al., 2008); [142]</td></tr><tr><td>• Elasticity (Janson et al., 2015); [131]</td></tr><tr><td>• Stiffness (Xia et al., 2017); [143]</td></tr><tr><td>• Hydrati... | <table><tr><td>Matrix Mechanical Characteristics that Impact Cell or Tissue Function</td></tr><tr><td>• Pore size and morphology (Chan et al., 2008); [142]</td></tr><tr><td>• Elasticity (Janson et al., 2015); [131]</td></tr></table> | <table><tr><td>Matrix Mechanical Characteristics that Impact Cell or Tissue Function</td></tr><tr><td>• Stiffness (Xia et al., 2017); [143]</td></tr><tr><td>• Hydration degree (Wu et al., 2006); [140]</td></tr></table> |
4bc2eb01b59d8b42609a7836cf86017f695fde75c10a873db745d5b2efc7e79f.png | simple | <table><tr><td>Name</td><td>SNP</td><td>Primer</td><td>Product length (bp)</td><td>Primer sequence (5’→3’)</td></tr><tr><td>rs17576</td><td>A/G</td><td>Forward</td><td></td><td>CAATTCACCCTCCCGCACTC</td></tr><tr><td></td><td></td><td>Reverse</td><td>222</td><td>GGAAGATGAATGGAAACTGG</td></tr><tr><td>rs2... | <table><tr><td>Name</td><td>SNP</td><td>Primer</td><td>Product length (bp)</td><td>Primer sequence (5’→3’)</td></tr></table> | <table><tr><td>rs17576</td><td>A/G</td><td>Forward</td><td></td><td>CAATTCACCCTCCCGCACTC</td></tr><tr><td></td><td></td><td>Reverse</td><td>222</td><td>GGAAGATGAATGGAAACTGG</td></tr><tr><td>rs2250889</td><td>C/G</td><td>Forward</td><td></td><td>GTATTTGTTCAAGGATGGGTG</td></tr><tr><td></td><td></td><td>Reverse</td><td>36... |
56a613f6f6c150d2996950551efbe510bd69debe377c353c8a2eac15a398f2f9.png | simple | <table><tr><td>Material</td><td>Tested</td><td>Ref.</td></tr><tr><td>Boron nitride, BN</td><td>Tested, in use, high efficiency, low erosion (0.02 mm<sup>3</sup>/C at 300 V)</td><td><sup>131, 139, 140</sup></td></tr><tr><td>Borosil, BN + SiO<sub>2</sub></td><td>Tested, in use, high efficiency, low wear</td><td><sup>131,... | <table><tr><td>Material</td><td>Tested</td><td>Ref.</td></tr><tr><td>Boron nitride, BN</td><td>Tested, in use, high efficiency, low erosion (0.02 mm3/C at 300 V)</td><td>131, 139, 140</td></tr><tr><td>Borosil, BN + SiO2</td><td>Tested, in use, high efficiency, low wear</td><td>131, 141</td></tr><tr><td>Alumina, Al2O3</... | <table><tr><td>Ultra-BN, uBN</td><td>Tested, high efficiency, very low wear</td><td>New result</td></tr></table> |
c31119842d47c98347302fedebfaf033986e95d71efab2ba903c26fb14988379.png | complex | <table><tr><td> </td><td colspan="2">HAZ</td><td colspan="2">WAZ</td></tr><tr><td> </td><td>Coefficient</td><td>Percent of ∆</td><td>Coefficient</td><td>Percent of ∆</td></tr><tr><td>Raw gap, ∆</td><td>.379</td><td>100.00</td><td>.248</td><td>100.00</td></tr><tr><td>Of which:</td><td> </td><td> </td><... | <table><tr><td></td><td>HAZ</td></tr><tr><td></td><td>Coefficient</td></tr><tr><td>Raw gap, ∆</td><td>.379</td></tr><tr><td>Of which:</td><td></td></tr><tr><td>Explained</td><td>.234</td></tr><tr><td>Unexplained</td><td>.145</td></tr></table> | <table><tr><td>HAZ</td><td colspan="2">WAZ</td></tr><tr><td>Percent of ∆</td><td>Coefficient</td><td>Percent of ∆</td></tr><tr><td>100.00</td><td>.248</td><td>100.00</td></tr><tr><td></td><td></td><td></td></tr><tr><td>61.7</td><td>.164</td><td>66.3</td></tr><tr><td>38.3</td><td>.083</td><td>33.7</td></tr></table> |
b130b366b6808684e907d159618ab92988b63f3290be4ca18afb6cc3995f277f.png | complex | <table><tr><td>Sub-scale</td><td>Attitudinal items</td><td colspan="2">Surgeon (n=41)</td><td colspan="2">Anaesthetist (n= 33)</td><td colspan="2">Nurse (n=33)</td></tr><tr><td> </td><td> </td><td>Mode</td><td>IQR</td><td>Mode</td><td>IQR</td><td>Mode</td><td>IQR</td></tr><tr><td> </td><td>There is little difference be... | <table><tr><td>Sub-scale</td><td>Attitudinal items</td><td colspan="2">Surgeon (n=41)</td><td colspan="2">Anaesthetist (n= 33)</td><td colspan="2">Nurse (n=33)</td></tr><tr><td></td><td></td><td>Mode</td><td>IQR</td><td>Mode</td><td>IQR</td><td>Mode</td><td>IQR</td></tr><tr><td></td><td>There is little difference betwe... | <table><tr><td></td><td>The complete checklist is used for every procedure in which I am involved in theatre.</td><td>5</td><td>1.5</td><td>1</td><td>3</td><td>5</td><td>1</td></tr><tr><td></td><td>When the checklist is being carried out, everyone in theatre stops what they are doing and listens until it is completed.<... |
0c9938f7f74263c62bce1af30e6d0f00f5e0409ec886504208224db36dbeb752.png | complex | <table><tr><td>Research problem</td><td>Tool/Instrument</td><td>Authors</td></tr><tr><td rowspan="7">Nausea and vomiting</td><td>Nausea Vomiting Pregnancy QOL (NVP QOL)</td><td>[8] Canada</td></tr><tr><td>Pregnancy Unique Questionnaire Emesis (PUQE)</td><td>[9] Canada, [10] Canada</td></tr><tr><td>McGill nausea questio... | <table><tr><td>Research problem</td><td>Tool/Instrument</td><td>Authors</td></tr><tr><td rowspan="3">Nau</td><td>Nausea Vomiting Pregnancy QOL (NVP QOL)</td><td>[8] Canada</td></tr><tr><td>Pregnancy Unique Questionnaire Emesis (PUQE)</td><td>[9] Canada, [10] Canada</td></tr><tr><td>McGill nausea question</td><td></td><... | <table><tr><td>Research problem</td><td>Tool/Instrument</td><td>Authors</td></tr><tr><td rowspan="5">sea and vomiting</td><td>naire</td><td>[11] Canada</td></tr><tr><td>Rhodes’ scores (RI)</td><td>[12] Canada</td></tr><tr><td>Short form – 36 (SF-36)</td><td>[13] China</td></tr><tr><td>SF-12, NVP specific QOL</td><td>[1... |
501c4ba6ff516a18de4c327ba2338caf07a7fc8daa8e5fa41992026f39465f67.png | complex | <table><tr><td>Laboratory site</td><td>Samples (<i>n</i>)</td><td colspan="2">Number of devices (<i>n</i>)</td><td colspan="2">Runs per day (<i>n</i>)</td><td>Approximately overall time requirement</td></tr><tr><td></td><td></td><td>Sprinter XL</td><td>EUROPattern</td><td>Screening</td><td>Titer</td><td></td></tr><tr><... | <table><tr><td>Laboratory site</td><td>Samples (n)</td><td colspan="2">Number of devices (n)</td><td colspan="2">Runs per day (n)</td><td>Approximately overall time requirement</td></tr><tr><td></td><td></td><td>Sprinter XL</td><td>EUROPattern</td><td>Screening</td><td>Titer</td><td></td></tr><tr><td>Houston, TX, USA</... | <table><tr><td>Laboratory site</td><td>Samples (n)</td><td colspan="2">Number of devices (n)</td><td colspan="2">Runs per day (n)</td><td>Approximately overall time requirement</td></tr><tr><td></td><td></td><td>Sprinter XL</td><td>EUROPattern</td><td>Screening</td><td>Titer</td><td></td></tr><tr><td>Tampa, FL, USA</td... |
2df8860ee557bb7692b3e3b47b3b47cf7cf173b76f0c9b0870dea45d819ddfcf.png | complex | <table><tr><td>School</td><td>Arm allocation<sup>a</sup></td><td>Number of girls in school</td><td>Provided consent (n, %)</td><td>Enrolled in intervention (n, %)</td><td colspan="2">Provided baseline data (n, %)</td><td>Mean weekly attendance during intervention (n, %)</td></tr><tr><td> </td><td> </td><td> </td><td> <... | <table><tr><td>School</td><td>Arm allocationa</td><td>Number of girls in school</td><td>Provided consent (n, %)</td><td>Enrolled in intervention (n, %)</td><td colspan="2">Provided baseline data (n, %)</td><td>Mean weekly attendance during intervention (n, %)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><t... | <table><tr><td>School</td><td>Arm allocationa</td><td>Number of girls in school</td><td>Provided consent (n, %)</td><td>Enrolled in intervention (n, %)</td><td colspan="2">Provided baseline data (n, %)</td><td>Mean weekly attendance during intervention (n, %)</td></tr><tr><td></td><td>A</td><td>0</td><td>0)</td><td>0.0... |
275e914a5e868f3acf45ecd7408bc238e77330c09d39c9c8a77a88782fce87e7.png | simple | <table><tr><td>Characteristic</td><td>β</td><td>Standard error</td><td><i>P</i></td></tr><tr><td>Baseline</td><td>-5.169</td><td>1.388</td><td>0.000</td></tr><tr><td>Proband breast cancer diagnosis ≤35 years</td><td>2.791</td><td>1.379</td><td>0.043</td></tr><tr><td>Proband breast cancer diagnosis 36-39 year... | <table><tr><td>Characteristic</td><td>β</td><td>Standard error</td><td>P</td></tr><tr><td>Baseline</td><td>-5.169</td><td>1.388</td><td>0.000</td></tr><tr><td>Proband breast cancer diagnosis ≤35 years</td><td>2.791</td><td>1.379</td><td>0.043</td></tr><tr><td>Proband breast cancer diagnosis 36-39 years</td><td>2.248</t... | <table><tr><td>Characteristic</td><td>β</td><td>Standard error</td><td>P</td></tr><tr><td>ee, breast cancer diagnosis 50-59 years</td><td>1.445</td><td>0</td><td>1</td></tr><tr><td>First degree, breast cancer diagnosis 60+ years</td><td>0.207</td><td>0.646</td><td>0.749</td></tr><tr><td>First degree, ovarian cancer at ... |
aff44afa7135e82abc33f11de7e5dbe6b226abfc14eba6837374a8e344fb5f1c.png | complex | <table><tr><td> </td><td>Normal thyroid (n.4)</td><td>Hyperplasia/Benign nodules (n.5)</td><td>Thyroid carcinoma (n.7)</td></tr><tr><td>Video intensity UCA<sub>IGg</sub></td><td colspan="3"> </td></tr><tr><td>Video intensity difference</td><td>11.3 (9.4-14.7)</td><td>12.2 (8.5-19.6)</td><td>19.4 (11.4-22.6)</td></tr><t... | <table><tr><td></td><td>Normal thyroid (n.4)</td><td>Hyperplasia/Benign nodules (n.5)</td><td>Thyroid carcinoma (n.7)</td></tr><tr><td>Video intensity UCAIGg</td><td colspan="3"></td></tr><tr><td>Video intensity difference</td><td>11.3 (9.4-14.7)</td><td>12.2 (8.5-19.6)</td><td>19.4 (11.4-22.6)</td></tr></table> | <table><tr><td>Video intensity UCAVEGFR2</td><td colspan="3"></td></tr><tr><td>Video intensity difference</td><td>10.9 (10.3-14.9)</td><td>13.3 (10.8-15.8)</td><td>30.1 (25.1-35.6)* §</td></tr></table> |
73525cea8b520738639021190ff42bc38f0aa5872e22bfafdf96a97ba09bb878.png | simple | <table><tr><td></td><td>Mechanism of action</td><td>Drugs</td><td>Trial (reference)</td><td>Study population</td><td>Benefits</td><td>Common severetoxicities</td></tr><tr><td>Apoptosis</td><td>PARP inhibitors</td><td>Olaparib</td><td>Phase II (127)</td><td>Recurrent/metastatic adult ES (failure to prior CH), <i>n</i> =... | <table><tr><td></td><td>Mechanism of action</td><td>Drugs</td><td>Trial (reference)</td><td>Study population</td><td>Benefits</td><td>Common severetoxicities</td></tr><tr><td>Apoptosis</td><td>PARP inhibitors</td><td>Olaparib</td><td>Phase II (127)</td><td>Recurrent/metastatic adult ES (failure to prior CH), n = 12 pat... | <table><tr><td></td><td></td><td></td><td>hase I (131)</td><td> cohort for sarcoma patients, n = 30 (sarcoma patients)</td><td>ependent)</td><td>Cytopenias</td></tr><tr><td></td><td>PI3K-AKT-mTOR pathway inhibitors</td><td>Ridaforolimus (mTOR INH)</td><td>Phase II (132)</td><td>Pre-treated advanced bone and STS, n = 21... |
d631f34543f7c4b4b4cf73eec2fe3723fb6ab147f16758cf65ea4153d3f52887.png | complex | <table><tr><td rowspan="2">Sample</td><td rowspan="2"><i>L</i> / cov</td><td colspan="6">Compression rates</td></tr><tr><td>Assembltrie</td><td>Assembltrie (corrected)</td><td>Orcom</td><td>BEETL</td><td>Mince</td><td>k-Path</td></tr><tr><td>SRR554369</td><td>100/25</td><td>0.369</td><td>0.345</td><td>0.518</td><td>1.1... | <table><tr><td rowspan="2">Sample</td><td rowspan="2">L / cov</td><td colspan="6">Compression rates</td></tr><tr><td>Assembltrie</td><td>Assembltrie (corrected)</td><td>Orcom</td><td>BEETL</td><td>Mince</td><td>k-Path</td></tr><tr><td>SRR554369</td><td>100/25</td><td>0.369</td><td>0.345</td><td>0.518</td><td>1.133</td>... | <table><tr><td rowspan="2">Sample</td><td rowspan="2">L / cov</td><td colspan="6">Compression rates</td></tr><tr><td>Assembltrie</td><td>Assembltrie (corrected)</td><td>Orcom</td><td>BEETL</td><td>Mince</td><td>k-Path</td></tr><tr><td>7</td><td>108/20</td><td>821</td><td>33</td><td>884</td><td></td><td>35</td><td>.707<... |
96cfe37fab46c4089201e16ffa83510b442f886e6c077ae1921769808f1dfa02.png | simple | <table><tr><td>Library</td><td>total reads</td><td>reads length(bp)</td><td>Total mapped</td><td>mapped%</td><td>mapped pairs</td><td>mapped paired%</td><td>Mapped genes<sup>*</sup></td></tr><tr><td>T1</td><td>23,708,937</td><td>101</td><td>33,274,003</td><td>70.17%</td><td>15,623,535</td><td>65.90%</td><td>15,594</td>... | <table><tr><td>Library</td><td>total reads</td><td>reads length(bp)</td><td>Total mapped</td><td>mapped%</td><td>mapped pairs</td><td>mapped paired%</td><td>Mapped genes*</td></tr><tr><td>T1</td><td>23,708,937</td><td>101</td><td>33,274,003</td><td>70.17%</td><td>15,623,535</td><td>65.90%</td><td>15,594</td></tr><tr><t... | <table><tr><td>Library</td><td>total reads</td><td>reads length(bp)</td><td>Total mapped</td><td>mapped%</td><td>mapped pairs</td><td>mapped paired%</td><td>Mapped genes*</td></tr><tr><td>T2</td><td>46,059,548</td><td>101</td><td>38,593,916</td><td>83.79%</td><td>18,494,595</td><td>80.31%</td><td>17,549</td></tr><tr><t... |
8cc4e07a12aac024065b66bb7d695266dd8c8949bf50d43fd351347e8da6068f.png | complex | <table><tr><td></td><td colspan="2">Flg22-responsive genes*</td><td colspan="2">Light-responsive genes**</td><td>Overlap genes</td><td><i>P</i>-value<sup>***</sup></td></tr><tr><td>Flg22-induced light-dependent genes</td><td>3579</td><td>(flg22-up)</td><td>2576</td><td>(light-dependent)</td><td>536</td><td>8.790e-24</t... | <table><tr><td></td><td colspan="2">Flg22-responsive genes*</td><td>Light-responsive genes**</td></tr><tr><td>Flg22-induced light-dependent genes</td><td>3579</td><td>(flg22-up)</td><td>2576</td></tr><tr><td>Flg22-induced light-repressed genes</td><td>3579</td><td>(flg22-up)</td><td>2161</td></tr><tr><td>Flg22-represse... | <table><tr><td>Light-responsive genes**</td><td>Overlap genes</td><td>P-value***</td></tr><tr><td>(light-dependent)</td><td>536</td><td>8.790e-24</td></tr><tr><td>(light-repressed)</td><td>239</td><td>1.084e-05</td></tr><tr><td>(light-dependent)</td><td>359</td><td>2.599e-04</td></tr><tr><td>(light-repressed)</td><td>3... |
f5e150fa393074bf230e007a1757f82f79e563f1ac9a687c7a3ad2959ac3b20c.png | complex | <table><tr><td rowspan="2">Patient No.</td><td rowspan="2">Ethnicity</td><td colspan="5">Biochemical findings</td><td rowspan="2">Phenotype</td><td rowspan="2"><i>ACADS</i> genotype</td></tr><tr><td>C4<sup>a</sup></td><td>C4/C2<sup>a</sup></td><td>C4/C3<sup>a</sup></td><td>C4/C8<sup>a</sup></td><td>EMA<sup>b</sup></td>... | <table><tr><td rowspan="2">Patient No.</td><td rowspan="2">Ethnicity</td><td colspan="5">Biochemical findings</td></tr><tr><td>C4a</td><td>C4/C2a</td><td>C4/C3a</td><td>C4/C8a</td><td>EMAb</td></tr><tr><td>1</td><td>R</td><td>1.53</td><td>0.21</td><td>1.35</td><td>40.38</td><td>N/A</td></tr><tr><td>9</td><td>R</td><td>... | <table><tr><td rowspan="2">Phenotype</td><td rowspan="2">ACADS genotype</td></tr><tr></tr><tr><td>microcephaly, DD/ID, marked hypotonus, horizontal nystagmus</td><td rowspan="9">c.310_312delGAG/c.310_312delGAG</td></tr><tr><td>DD/ID, apnoic pause, bleeding into the adrenal glands in the neonatal age, hypoglycaemia</td>... |
262b03b0c3ed1c1e083dfdac666c8e1661a058726f2a5970970f521a1a3c0177.png | complex | <table><tr><td rowspan="2"></td><td></td><td>Non-surgical <i>n</i> = 261</td><td>Bariatric surgery <i>n</i> = 301</td><td>Adjusted for gender/age/BMI</td><td></td><td></td></tr><tr><td>Range</td><td>Mean (SD)</td><td>Mean (SD)</td><td>F</td><td><i>P</i></td><td>ηp<sup>2</sup></td></tr><tr><td colspan="7">Family ob... | <table><tr><td rowspan="2"></td><td></td><td>Non-surgical n = 261</td><td>Bariatric surgery n = 301</td><td>Adjusted for gender/age/BMI</td><td></td><td></td></tr><tr><td>Range</td><td>Mean (SD)</td><td>Mean (SD)</td><td>F</td><td>P</td><td>ηp2</td></tr></table> | <table><tr><td colspan="7">Family obesity</td></tr><tr><td>- parent/sibling + as a child</td><td>0–2</td><td>1.0 (0.7)</td><td>1.3 (0.7)</td><td>8.98</td><td><0.01</td><td>0.017</td></tr><tr><td>- partner + own children</td><td>0–2</td><td>0.7 (0.7)</td><td>0.7 (0.6)</td><td>0.01</td><td>0.93</td><td></td></tr><tr><td ... |
dc1a788177e60ac47724168b1fcec85bab74be3bb50fdbb303f5eedb5fb8b195.png | simple | <table><tr><td>GeneID</td><td>Gene Description</td><td>miRNAs</td><td>miRDB (target score)</td><td>TargetScan (Context + Percentile)</td></tr><tr><td>ABHD3</td><td>Abhydrolase domain containing 3</td><td>miR-1244, miR-130a, miR-205</td><td>74, > 85</td><td>84</td></tr><tr><td>CCNJ</td><td>Cyclin J</td><td>miR-205-5p... | <table><tr><td>GeneID</td><td>Gene Description</td><td>miRNAs</td><td>miRDB (target score)</td><td>TargetScan (Context + Percentile)</td></tr><tr><td>ABHD3</td><td>Abhydrolase domain containing 3</td><td>miR-1244, miR-130a, miR-205</td><td>74, > 85</td><td>84</td></tr><tr><td>CCNJ</td><td>Cyclin J</td><td>miR-205-5p</t... | <table><tr><td>GeneID</td><td>Gene Description</td><td>miRNAs</td><td>miRDB (target score)</td><td>TargetScan (Context + Percentile)</td></tr><tr><td>VEGFA</td><td>Vascular endothelial growth factor A</td><td>miR-205, miR-15b</td><td>79</td><td>97</td></tr><tr><td>FGD4</td><td>RhoGEF and PH domain containing 4</td><td>... |
9a62fc7fa57489bc7287ff6cc3263d74a083c7b636fb1c3968d83702520b4643.png | simple | <table><tr><td>Diagnosis</td><td><i>n</i></td></tr><tr><td>Breast cancer</td><td>200</td></tr><tr><td>Glioma</td><td>144</td></tr><tr><td>Cervical carcinoma</td><td>117</td></tr><tr><td>Meningioma</td><td>72</td></tr><tr><td>Pituary adenoma</td><td>50</td></tr><tr><td>Cerebral lymphoma</td><td>49</td></tr></table> | <table><tr><td>Diagnosis</td><td>n</td></tr><tr><td>Breast cancer</td><td>200</td></tr><tr><td>Glioma</td><td>144</td></tr><tr><td>Cervical carcinoma</td><td>117</td></tr><tr><td>Meningioma</td><td>72</td></tr><tr><td>Pituary adenoma</td><td>50</td></tr></table> | <table><tr><td>Cerebral lymphoma</td><td>49</td></tr></table> |
94750d3460c6ee2c4b6ef305bad409c0ccca224b91f8defcbfe8ffe43ff4047a.png | complex | <table><tr><td rowspan="3"></td><td colspan="4">Prague</td><td colspan="4">4 cities</td></tr><tr><td colspan="2">CAPI</td><td colspan="2">CAWI</td><td colspan="2">CAPI</td><td colspan="2">CAWI</td></tr><tr><td><i>coeff.</i></td><td><i>s.e.</i></td><td><i>coeff.</i></td><td><i>s.e.</i></td><td><i>coeff.</i></td><td><i>s... | <table><tr><td></td><td colspan="4">Prague</td><td colspan="4">4 cities</td></tr></table> | <table><tr><td rowspan="2"></td><td colspan="2">CAPI</td><td colspan="2">CAWI</td><td colspan="2">CAPI</td><td colspan="2">CAWI</td></tr><tr><td>coeff.</td><td>s.e.</td><td>coeff.</td><td>s.e.</td><td>coeff.</td><td>s.e.</td><td>coeff.</td><td>s.e.</td></tr><tr><td>α</td><td>2.26</td><td>0.312</td><td>1.25</td><td>0.26... |
68bf6013a27a94ee070d99fa6b144f7c5e569b33358471e1936ecbc991b1db58.png | simple | <table><tr><td></td><td>Food resource referrals - 2016</td></tr><tr><td>Pediatrics clinic</td><td>438</td></tr><tr><td>Internal medicine clinic</td><td>140</td></tr><tr><td>Family medicine clinic</td><td>246</td></tr><tr><td>Emergency department</td><td>55 (25 Attending Physicians, 22 Resident Physicians, 8 Physician A... | <table><tr><td></td></tr><tr><td>Pediatrics clinic</td></tr><tr><td>Internal medicine clinic</td></tr><tr><td>Family medicine clinic</td></tr><tr><td>Emergency department</td></tr><tr><td>Psychiatry clinic</td></tr></table> | <table><tr><td>Food resource referrals - 2016</td></tr><tr><td>438</td></tr><tr><td>140</td></tr><tr><td>246</td></tr><tr><td>55 (25 Attending Physicians, 22 Resident Physicians, 8 Physician Assistants)</td></tr><tr><td>52</td></tr></table> |
274ba4ecec724c731e0d45ef5acd0bb4f01f06f65870af25b7925d61351f5421.png | simple | <table><tr><td>Reference</td><td>Sample number</td><td>Histotype</td><td>Results</td></tr><tr><td>Sawabata et al. (17)</td><td>9</td><td>NSCLC</td><td>CTC-positive in 4/9 patients. No recurrence after surgery</td></tr><tr><td>Bevilacqua et al. (19)</td><td>5</td><td>SCLC</td><td>CTC have a role in SCLC patients diagnos... | <table><tr><td>Reference</td><td>Sample number</td></tr><tr><td>Sawabata et al. (17)</td><td>9</td></tr><tr><td>Bevilacqua et al. (19)</td><td>5</td></tr><tr><td>Tanaka et al. (20)</td><td>150</td></tr><tr><td>Hou et al. (21)</td><td>50</td></tr><tr><td>Naito et al. (22)</td><td>51</td></tr><tr><td>Hiltermann et al. (2... | <table><tr><td>Histotype</td><td>Results</td></tr><tr><td>NSCLC</td><td>CTC-positive in 4/9 patients. No recurrence after surgery</td></tr><tr><td>SCLC</td><td>CTC have a role in SCLC patients diagnosis</td></tr><tr><td>NSCLC and SCLC</td><td>CTC well differentiate stage I from stage IV tumors</td></tr><tr><td>SCLC</td... |
3acd767fddfdac5cc2a92be4f9fb8bddd8c876ca3ecce8164966a887762ff948.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2"><i>B</i></td><td rowspan="2"><i>S.E.</i></td><td rowspan="2"><i>Wald</i></td><td rowspan="2"><i>p</i></td><td rowspan="2"><i>OR</i></td><td colspan="2">95% CI</td></tr><tr><td>Min</td><td>Max</td></tr><tr><td>Predisposing characteristics</td><td></td><td></td><td></td><td... | <table><tr><td rowspan="2"></td><td rowspan="2">B</td><td rowspan="2">S.E.</td><td rowspan="2">Wald</td><td rowspan="2">p</td><td rowspan="2">OR</td><td colspan="2">95% CI</td></tr><tr><td>Min</td><td>Max</td></tr><tr><td>Predisposing characteristics</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></... | <table><tr><td rowspan="2"></td><td rowspan="2">B</td><td rowspan="2">S.E.</td><td rowspan="2">Wald</td><td rowspan="2">p</td><td rowspan="2">OR</td><td colspan="2">95% CI</td></tr><tr><td>Min</td><td>Max</td></tr><tr><td>Just to meet basic needs</td><td>0.422</td><td>0.263</td><td>2.570</td><td>0.109</td><td>1.524</td... |
6583eff8b804f10ce468e6c57a80cf9bcfd3c3ed3fa93e0f07f14a029e7ae122.png | simple | <table><tr><td> </td><td>ASRV</td><td>DGRV</td><td>ACRV</td><td>IIRV</td><td>PVRV</td><td>FV3</td><td>SSTIV</td><td>CH8/96</td><td>ESV/ECV</td><td>RTV</td><td>TRV</td></tr><tr><td>ASRV</td><td> </td><td>98.0</td><td>99.6</td><td>96.4</td><td>98.0</td><td>99.6</td><td>99.4</td><td>98.2</td><td>96.4</td><td>98.2</td><td>... | <table><tr><td></td><td>ASRV</td><td>DGRV</td><td>ACRV</td><td>IIRV</td><td>PVRV</td><td>FV3</td><td>SSTIV</td><td>CH8/96</td><td>ESV/ECV</td><td>RTV</td><td>TRV</td></tr><tr><td>ASRV</td><td></td><td>98.0</td><td>99.6</td><td>96.4</td><td>98.0</td><td>99.6</td><td>99.4</td><td>98.2</td><td>96.4</td><td>98.2</td><td>98... | <table><tr><td></td><td>ASRV</td><td>DGRV</td><td>ACRV</td><td>IIRV</td><td>PVRV</td><td>FV3</td><td>SSTIV</td><td>CH8/96</td><td>ESV/ECV</td><td>RTV</td><td>TRV</td></tr><tr><td>IIRV</td><td>95.8</td><td>96.4</td><td>95.8</td><td></td><td>96.8</td><td>96.8</td><td>97.0</td><td>98.2</td><td>100</td><td>96.2</td><td>96.... |
bc7ff0ddd72cf51d2146f72c9fa0826723dd4d4ab8d36245fb7c24cd7b706223.png | complex | <table><tr><td rowspan="2">Characteristic</td><td>Lifestyle</td><td>Preventive screening</td><td>Choosing treatments</td><td>Choosing specialists</td><td>Choosing medications</td><td>Diagnostic testing</td></tr><tr><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>O... | <table><tr><td rowspan="2">Characteristic</td><td>Lifestyle</td><td>Preventive screening</td><td>Choosing treatments</td><td>Choosing specialists</td><td>Choosing medications</td><td>Diagnostic testing</td></tr><tr><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>OR [95% CI]</td><td>O... | <table><tr><td colspan="7">Patient activation</td></tr><tr><td>Level 1</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td><td>Ref</td></tr><tr><td>Level 2</td><td>1.33 [0.86, 2.08]</td><td>1.62 [1.08, 2.44]</td><td>1.06 [0.70, 1.60]</td><td>1.13 [0.74, 1.70]</td><td>1.47 [0.97, 2.22]</td><td>0.92 [0.61, 1.... |
ac2b6fed540529f7f36278a6b21860f37d75c6bfcec9d0d254784ea025e39e46.png | complex | <table><tr><td>Antibiotic class</td><td>Multidrug-resistant (n = 226)</td><td>Non-multidrug-resistant (n = 514)</td><td><i>P</i>-value</td></tr><tr><td>Aminoglycosides</td><td>226 (29.2%)</td><td>505 (91.1%)</td><td><0.001</td></tr><tr><td>Antipseudomonal carbapenems</td><td>226 (15.0%)</td><td>508 (84.6%)</td><td>&... | <table><tr><td>Antibiotic class</td><td>Multidrug-resistant (n = 226)</td><td>Non-multidrug-resistant (n = 514)</td><td>P-value</td></tr><tr><td>Aminoglycosides</td><td>226 (29.2%)</td><td>505 (91.1%)</td><td><0.001</td></tr><tr><td>Antipseudomonal carbapenems</td><td>226 (15.0%)</td><td>508 (84.6%)</td><td><0.001</td>... | <table><tr><td>Antipseudomonal fluoroquinolones</td><td>222 (21.5%)</td><td>502 (88.4%)</td><td><0.001</td></tr><tr><td>Antipseudomonal penicillins +</td><td rowspan="2">221 (22.2%)</td><td rowspan="2">502 (89.0%)</td><td rowspan="2"><0.001</td></tr><tr><td>β-lactamase inhibitors</td></tr><tr><td>Monobactams</td><td>15... |
53e1b1700650b72ce62c9f903aff6784642ee82ff9ab44bd02b4c48142c1ec67.png | simple | <table><tr><td>Variable</td><td>No. of missing data</td></tr><tr><td>Expenditure</td><td>2</td></tr><tr><td>Family support</td><td>2</td></tr><tr><td>MBI at admission</td><td>10</td></tr><tr><td>WHOQOL-BREF at admission</td><td>15</td></tr><tr><td>Number of joints with limited ROM at admission</td><td>50</td></tr><tr><... | <table><tr><td>Variable</td><td>No. of missing data</td></tr><tr><td>Expenditure</td><td>2</td></tr><tr><td>Family support</td><td>2</td></tr><tr><td>MBI at admission</td><td>10</td></tr><tr><td>WHOQOL-BREF at admission</td><td>15</td></tr><tr><td>Number of joints with limited ROM at admission</td><td>50</td></tr><tr><... | <table><tr><td>WHOQOL-BREF at discharge</td><td>12</td></tr><tr><td>Number of joints with limited ROM at discharge</td><td>18</td></tr><tr><td>Work status after discharge</td><td>4</td></tr></table> |
47f8e6ab0d6218487626a38d089a201bdd9ce2254c4c66b89443bc52375d3b88.png | complex | <table><tr><td>Name</td><td>Forward</td><td>Reverse</td><td>Accession number</td><td>Transcripts length (base pairs)</td><td>Primer efficiency (%)</td></tr><tr><td colspan="6">Housekeeping gene study</td></tr><tr><td> <i>Actb</i></td><td>agccatgtacgtagccatcc</td><td>accctcatagatgggcacag</td><td>NM_031144.3</td><td>115<... | <table><tr><td>Name</td></tr><tr><td>Housekeeping gene study</td></tr><tr><td>Actb</td></tr><tr><td>Gapdh</td></tr><tr><td>Hmbs</td></tr><tr><td>Hprt1</td></tr><tr><td>Ppia</td></tr><tr><td>Ppib</td></tr><tr><td>Rpl13a</td></tr><tr><td>Sdha</td></tr><tr><td>Gene expression study</td></tr><tr><td>Ppiba</td></tr><tr><td>... | <table><tr><td>Forward</td><td>Reverse</td><td>Accession number</td><td>Transcripts length (base pairs)</td><td>Primer efficiency (%)</td></tr><tr><td colspan="5">Housekeeping gene study</td></tr><tr><td>agccatgtacgtagccatcc</td><td>accctcatagatgggcacag</td><td>NM_031144.3</td><td>115</td><td>100.8</td></tr><tr><td>gtg... |
49343c92f6814621872ffc73bf448a5085dc9c4d27132adffe1f266536054984.png | complex | <table><tr><td rowspan="2">Response</td><td colspan="2">Medical <i>n</i> = 779</td><td colspan="2">Dental <i>n</i> = 347</td><td rowspan="2"><i>P</i> value</td></tr><tr><td>Mean (SD)</td><td>Med (IOR)</td><td>Mean (SD)</td><td>Med (IQR)</td></tr><tr><td>My muscles become tense</td><td>1.88 (0.89)</td><td>2.0 (1)</td><t... | <table><tr><td rowspan="2">Response</td><td colspan="2">Medical n = 779</td><td colspan="2">Dental n = 347</td><td rowspan="2">P value</td></tr><tr><td>Mean (SD)</td><td>Med (IOR)</td><td>Mean (SD)</td><td>Med (IQR)</td></tr><tr><td>My muscles become tense</td><td>1.88 (0.89)</td><td>2.0 (1)</td><td>1.99 (0.88)</td><td... | <table><tr><td rowspan="2">Response</td><td colspan="2">Medical n = 779</td><td colspan="2">Dental n = 347</td><td rowspan="2">P value</td></tr><tr><td>Mean (SD)</td><td>Med (IOR)</td><td>Mean (SD)</td><td>Med (IQR)</td></tr><tr><td>I feel nauseated and sick to my stomach</td><td>1.48 (0.79)</td><td>1.0 (1)</td><td>1.2... |
9a17756020cd8aad583b5c835d1aadcd044ccbec2df95e6a3ce053183ee33860.png | simple | <table><tr><td>genes percontig</td><td>number ofcontigs</td><td>contigs perscaffold</td><td>number ofscaffolds</td><td><i>Vitis </i>genes perdeleted block</td><td>number ofdeletions</td></tr><tr><td>1</td><td>1699</td><td>1</td><td>469</td><td>1</td><td>2253</td></tr><tr><td>2</td><td>612</td><td>2</td><td>181</td><td>... | <table><tr><td>genes percontig</td><td>number ofcontigs</td><td>contigs perscaffold</td><td>number ofscaffolds</td><td>Vitis genes perdeleted block</td><td>number ofdeletions</td></tr><tr><td>1</td><td>1699</td><td>1</td><td>469</td><td>1</td><td>2253</td></tr><tr><td>2</td><td>612</td><td>2</td><td>181</td><td>2</td><... | <table><tr><td>genes percontig</td><td>number ofcontigs</td><td>contigs perscaffold</td><td>number ofscaffolds</td><td>Vitis genes perdeleted block</td><td>number ofdeletions</td></tr><tr><td>7</td><td>1</td><td>7</td><td>5</td><td></td><td></td></tr><tr><td>8</td><td>55</td><td>8</td><td>19</td><td>8</td><td>1</td></t... |
07c54ace43af6d3c6682c6611a0a9bd314325892fe1e296b3604c9d4dfe2b1b0.png | complex | <table><tr><td></td><td colspan="2">Number of OTU</td><td colspan="3">The Mean Proportion of OTUs in the Group (%)</td><td></td><td></td></tr><tr><td>Taxon</td><td>Moderate exposure</td><td>Low exposure</td><td>Moderate exposure <sup>a</sup></td><td>Low exposure <sup>a</sup></td><td><i>p</i>-value <sup>a</sup></td><td>... | <table><tr><td></td><td colspan="2">Number of OTU</td><td colspan="3">The Mean Proportion of OTUs in the Group (%)</td><td></td><td></td></tr><tr><td>Taxon</td><td>Moderate exposure</td><td>Low exposure</td><td>Moderate exposure a</td><td>Low exposure a</td><td>p-value a</td><td>Odds ratio b</td><td>95% CI b</td></tr><... | <table><tr><td>Proteobacteria/Pasteurellaceae</td><td>1311</td><td>542</td><td>6.2%</td><td>3.5%</td><td>0.34</td><td>2.39</td><td>2.15–2.64</td></tr></table> |
8b77a0484bdc5109b35b2558e07ff208df3c2f80ee74712cbbf8fb9c11d19f9a.png | simple | <table><tr><td>Primers</td><td>Sequences</td><td>Nucleotide position</td></tr><tr><td></td><td>First round</td><td></td></tr><tr><td>Sense</td><td>5′-TTCATACAGTAACGCCCAGC-3′</td><td>259–278</td></tr><tr><td>Antisense</td><td>5′-GCAACTACAGGGATTGTAAGGG-3′</td><td>808–829</td></tr><tr><... | <table><tr><td>Primers</td></tr><tr><td></td></tr><tr><td>Sense</td></tr><tr><td>Antisense</td></tr><tr><td></td></tr><tr><td>Sense</td></tr><tr><td>Antisense</td></tr></table> | <table><tr><td>Sequences</td><td>Nucleotide position</td></tr><tr><td>First round</td><td></td></tr><tr><td>5′-TTCATACAGTAACGCCCAGC-3′</td><td>259–278</td></tr><tr><td>5′-GCAACTACAGGGATTGTAAGGG-3′</td><td>808–829</td></tr><tr><td>Second round</td><td></td></tr><tr><td>5′GCCTTGTGTTTCTATGTTTGC-3′</td><td>277–297</td></tr... |
3f1573908d74d1dbe09da84fc9a246ac1971ea4bd1d26cf0981da4dc632ab5dc.png | complex | <table><tr><td></td><td></td><td></td><td colspan="2">(% completing step correctly) (n = 15)</td><td></td></tr><tr><td></td><td></td><td>Description of step</td><td>End of training<sup>a</sup></td><td>7 months post training<sup>b</sup></td><td>Most common error(s)</td></tr><tr><td>1</td><td></td><td>Work surface disinf... | <table><tr><td></td><td></td><td></td><td colspan="2">(% completing step correctly) (n = 15)</td><td></td></tr><tr><td></td><td></td><td>Description of step</td><td>End of traininga</td><td>7 months post trainingb</td><td>Most common error(s)</td></tr><tr><td>1</td><td></td><td>Work surface disinfected with alcohol</td... | <table><tr><td></td><td></td><td></td><td colspan="2">(% completing step correctly) (n = 15)</td><td></td></tr><tr><td></td><td></td><td>Description of step</td><td>End of traininga</td><td>7 months post trainingb</td><td>Most common error(s)</td></tr><tr><td>24</td><td>T</td><td>Selects appropriate paracetamol dose</t... |
434dfaa2fe26fb6ad7ca4d5311810ba7652c389713a5d0330eac8c0311e06f85.png | simple | <table><tr><td>Intervention</td><td>n</td><td>Duration</td><td>% of analyzed time</td></tr><tr><td>Respiratory support via mask</td><td>46</td><td>8.8 (1.5-28.5) min</td><td>46.9 (15.8-97.6)<sup>b</sup></td></tr><tr><td> Sustained inflations</td><td>15</td><td>8.5 (1.8–13.8) s</td><td>2.6(0.2-8.4)<sup>c</sup></td... | <table><tr><td>Intervention</td><td>n</td><td>Duration</td><td>% of analyzed time</td></tr><tr><td>Respiratory support via mask</td><td>46</td><td>8.8 (1.5-28.5) min</td><td>46.9 (15.8-97.6)b</td></tr></table> | <table><tr><td>Intervention</td><td>n</td><td>Duration</td><td>% of analyzed time</td></tr><tr><td>Sustained inflations</td><td>15</td><td>8.5 (1.8–13.8) s</td><td>2.6(0.2-8.4)c</td></tr><tr><td>Mechanical ventilation</td><td>7</td><td>53.1 (6.9-128.5) s</td><td>11.6(0.5-69.8)c</td></tr><tr><td>Suctioning</td><td>31</t... |
7f5bed28e756aa7a7cf1fb62724fa7e79e21f35672f5ff3a66f1c31e28ab4f1e.png | simple | <table><tr><td>Patients with total lipid profile</td><td>All patients (n = 2,009)</td><td>Very high risk* (n = 1,649)</td><td>High Risk (n = 58)</td><td>Moderate risk (n = 214)</td><td>Low Risk (n = 88)</td></tr><tr><td>LDL-C not at target [%]<sup>†</sup></td><td>61.8</td><td>69.5</td><td>56.9</td><td>29.0</td><t... | <table><tr><td>Patients with total lipid profile</td><td>All patients (n = 2,009)</td><td>Very high risk* (n = 1,649)</td><td>High Risk (n = 58)</td><td>Moderate risk (n = 214)</td></tr><tr><td>LDL-C not at target [%]†</td><td>61.8</td><td>69.5</td><td>56.9</td><td>29.0</td></tr><tr><td>Low HDL-C (<1.0 [men]/1.2 [women... | <table><tr><td>Low Risk (n = 88)</td></tr><tr><td>Δ</td></tr><tr><td>33.0</td></tr><tr><td>37.5</td></tr><tr><td>(n= 97)</td></tr><tr><td>Δ</td></tr><tr><td>33.7</td></tr><tr><td>39.6</td></tr></table> |
c507f2a413a100a82451dca7a3cea9d8e10117621d877632cd65f7d7a4bab2a4.png | simple | <table><tr><td>Year</td><td>Month</td><td>BMI</td><td>Treatment</td><td>Dose</td><td>Performance status</td></tr><tr><td>2011</td><td></td><td>31.2</td><td></td><td></td><td></td></tr><tr><td>2013</td><td>Feb</td><td>29.4</td><td>FLOX C1</td><td>Oxaliplatin: 150 mg Fluorouracil: 950 mg Calciumfolinat: 110 mg</td><td>0<... | <table><tr><td>Year</td><td>Month</td><td>BMI</td><td>Treatment</td><td>Dose</td><td>Performance status</td></tr><tr><td>2011</td><td></td><td>31.2</td><td></td><td></td><td></td></tr><tr><td>2013</td><td>Feb</td><td>29.4</td><td>FLOX C1</td><td>Oxaliplatin: 150 mg Fluorouracil: 950 mg Calciumfolinat: 110 mg</td><td>0<... | <table><tr><td>Year</td><td>Month</td><td>BMI</td><td>Treatment</td><td>Dose</td><td>Performance status</td></tr><tr><td></td><td></td><td></td><td>evacizumab C1</td><td>mg</td><td>-2</td></tr><tr><td></td><td>Aug</td><td></td><td>Capecitabine/ Bevacizumab C2</td><td>500 mg × 2/ 350 mg</td><td>0-1</td></tr><tr><td></td... |
da570045c0cee8953be2362401ba0333aab80623e8e1d0f73fb758a8d36b918d.png | simple | <table><tr><td>Disc level</td><td>Overall</td><td>Men</td><td>Women</td></tr><tr><td>L1-L2</td><td>21.9 ± 3.8</td><td>21.6 ± 3.9</td><td>22.1 ± 3.8</td></tr><tr><td>L2-L3</td><td>24.0 ± 4.5</td><td>24.4 ± 4.6</td><td>23.7 ± 4.5</td></tr><tr><td>L3-L4</td><td>26.2 ± 5.5</td><td>26.5 &#... | <table><tr><td>Disc level</td><td>Overall</td><td>Men</td></tr><tr><td>L1-L2</td><td>21.9 ± 3.8</td><td>21.6 ± 3.9</td></tr><tr><td>L2-L3</td><td>24.0 ± 4.5</td><td>24.4 ± 4.6</td></tr><tr><td>L3-L4</td><td>26.2 ± 5.5</td><td>26.5 ± 5.0</td></tr><tr><td>L4-L5</td><td>26.9 ± 6.5</td><td>27.0 ± 6.1</td></tr><tr><td>L5-S1... | <table><tr><td>Women</td></tr><tr><td>22.1 ± 3.8</td></tr><tr><td>23.7 ± 4.5</td></tr><tr><td>26.0 ± 5.7</td></tr><tr><td>26.8 ± 6.8</td></tr><tr><td>28.0 ± 8.0</td></tr></table> |
2b8953bc0365f0b0a4f17e658a86c9df6a31c984bec6031dbd792be028c0b5e4.png | complex | <table><tr><td rowspan="2"> </td><td colspan="3">Placebo yoghurt group</td><td colspan="3">Plant stanol yoghurt group</td><td rowspan="2">p<sup>b</sup></td></tr><tr><td>Baseline</td><td>Intervention</td><td>Change (%)</td><td>Baseline</td><td>Intervention</td><td>Change (%)</td></tr><tr><td>Total cholesterol (mg/dl)</t... | <table><tr><td rowspan="2"></td></tr><tr></tr><tr><td>Total cholesterol (mg/dl)</td></tr><tr><td>LDL cholesterol (mg/dl)</td></tr><tr><td>HDL cholesterol (mg/dl)</td></tr><tr><td>Triglycerides (mg/dl)</td></tr><tr><td>VLDL cholesterol (mg/dl)</td></tr><tr><td>Non-HDL cholesterol (mg/dl)</td></tr><tr><td>Apolipoprotein ... | <table><tr><td colspan="3">Placebo yoghurt group</td><td colspan="3">Plant stanol yoghurt group</td><td rowspan="2">pb</td></tr><tr><td>Baseline</td><td>Intervention</td><td>Change (%)</td><td>Baseline</td><td>Intervention</td><td>Change (%)</td></tr><tr><td>233.4 ± 26.83</td><td>235.0 ± 23.75</td><td>1.2 ± 8.11</td><t... |
5a6d033b54f1eba8c519e71e3dbd4c150e4ee451b8877152ea1a8d5d4595fe76.png | simple | <table><tr><td></td><td>Center 1Southeast</td><td>Center 2Southeast</td><td>Center 3Southeast</td><td>Center 4Southeast</td><td>Center 5South</td><td>Center 6Northeast</td><td>Center 7Center-West</td><td>Total</td></tr><tr><td>DR-absent</td><td>109 (60.6 %)</td><td>118 (45.9 %)</td><td>71 (41.0 %)</td><td>31 (32.6 %)</... | <table><tr><td></td><td>Center 1Southeast</td><td>Center 2Southeast</td><td>Center 3Southeast</td><td>Center 4Southeast</td><td>Center 5South</td><td>Center 6Northeast</td><td>Center 7Center-West</td><td>Total</td></tr><tr><td>DR-absent</td><td>109 (60.6 %)</td><td>118 (45.9 %)</td><td>71 (41.0 %)</td><td>31 (32.6 %)</... | <table><tr><td></td><td>Center 1Southeast</td><td>Center 2Southeast</td><td>Center 3Southeast</td><td>Center 4Southeast</td><td>Center 5South</td><td>Center 6Northeast</td><td>Center 7Center-West</td><td>Total</td></tr><tr><td>DR-NP mild</td><td>35 (19.4 %)</td><td>91 (35.4 %)</td><td>53 (30.6 %)</td><td>33 (34.7 %)</t... |
c4f0ca79852fcbfd07bd36d721581461ef939b44125b8f8ba4880e78ad6f7eb8.png | simple | <table><tr><td></td><td>11/15/13</td><td>11/20/13</td><td>1/8/14</td><td>5/26/14</td></tr><tr><td>Total T (2–45 ng/dL)</td><td>337</td><td>281</td><td>230</td><td><i>288</i></td></tr><tr><td>Free T (0.1–6.4 pg/mL)</td><td></td><td>41.2</td><td>42.4</td><td><i>55.4</i></td></tr><tr><td>DHEA (<1185 mcg/dL)... | <table><tr><td></td><td>11/15/13</td><td>11/20/13</td><td>1/8/14</td><td>5/26/14</td></tr><tr><td>Total T (2–45 ng/dL)</td><td>337</td><td>281</td><td>230</td><td>288</td></tr><tr><td>Free T (0.1–6.4 pg/mL)</td><td></td><td>41.2</td><td>42.4</td><td>55.4</td></tr><tr><td>DHEA (<1185 mcg/dL)</td><td>117</td><td></td><td... | <table><tr><td>Estradiol (5–38 pg/mL)</td><td></td><td></td><td>23</td></tr><tr><td>FSH (0–14 mIU/mL)</td><td>86.5</td><td></td><td></td></tr><tr><td>LH (0–14 mIU/mL)</td><td>42.7</td><td></td><td></td></tr><tr><td>17‐hydroxyprogesterone (<51 ng/dL)</td><td></td><td></td><td>26</td></tr><tr><td>Prolactin (<20 ng/mL)</t... |
6f523ac02ba4799a1c703e1aaed32e8d82bfa26dd685eb185d52df468ae51fca.png | complex | <table><tr><td>Model</td><td>R<sup>2</sup></td><td>AIC</td><td>∆AIC</td><td>Model parameters</td><td>Parameter estimate</td></tr><tr><td colspan="6"><i>Climate variables only – Above 1300 m</i></td></tr><tr><td rowspan="2">1</td><td rowspan="2">0.50</td><td rowspan="2">−217.3</td><td rowspan="2">0</td... | <table><tr><td>Model</td><td>R2</td><td>AIC</td><td>∆AIC</td><td>Model parameters</td><td>Parameter estimate</td></tr><tr><td colspan="6">Climate variables only – Above 1300 m</td></tr><tr><td rowspan="2">1</td><td rowspan="2">0.50</td><td rowspan="2">−217.3</td><td rowspan="2">0</td><td>Precipitation – 6 month lag</td... | <table><tr><td>Model</td><td>R2</td><td>AIC</td><td>∆AIC</td><td>Model parameters</td><td>Parameter estimate</td></tr><tr><td>1</td><td>0.69</td><td>−232.3</td><td>0</td><td>Nut harvest – 4 mo. Lag</td><td>0.53</td></tr><tr><td rowspan="2">2</td><td rowspan="2">0.68</td><td rowspan="2">−231.0</td><td rowspan="2">1.3</t... |
bae284b7c8f1cb679ef7beb52a14005d5e173609d8fd95f5a687a9403cc57171.png | simple | <table><tr><td>Indexes</td><td>T1</td><td>T2</td><td>CK</td></tr><tr><td>CH<sub>4</sub> : O<sub>2</sub></td><td>90:10</td><td>99:1</td><td>–</td></tr><tr><td>Dissolved O<sub>2</sub> (mg l<sup>−1</sup>)</td><td>3.96 ± 0.09</td><td>0.24 ± 0.01</td><td>–</td></tr><tr><td>Methane oxidation activ... | <table><tr><td>Indexes</td></tr><tr><td>CH4 : O2</td></tr><tr><td>Dissolved O2 (mg l−1)</td></tr><tr><td>Methane oxidation activity (μmol g VSS−1 day−1)</td></tr><tr><td>Denitrification activity (μmol g VSS−1 day−1)</td></tr><tr><td>Nitrite consumption rate</td></tr><tr><td>Nitrate consumption rate</td></tr><tr><td>For... | <table><tr><td>T1</td><td>T2</td><td>CK</td></tr><tr><td>90:10</td><td>99:1</td><td>–</td></tr><tr><td>3.96 ± 0.09</td><td>0.24 ± 0.01</td><td>–</td></tr><tr><td>640.16 ± 88.76</td><td>354.21 ± 45.62</td><td>–</td></tr><tr><td></td><td></td><td></td></tr><tr><td>68.39 ± 2.90</td><td>46.50 ± 6.19</td><td>28.03 ± 1.59</t... |
de88d800c2e7fa5fa1941ba0ff65d14f47535be5bc1fa3e36d0860f60e320f2c.png | simple | <table><tr><td>Constructs</td><td>mutation</td><td>XMRV p53</td><td>XMRV p58</td></tr><tr><td>pVP62 (WT)</td><td>None</td><td>+</td><td>+</td></tr><tr><td>pVP62Δgg0</td><td>_ to A (nt 372)</td><td>-</td><td>-</td></tr><tr><td>pVP62Δgg1</td><td>C to AT (nt 382)</td><td>-</td><td>-</td></tr><tr><td>pVP62Δg... | <table><tr><td>Constructs</td><td>mutation</td><td>XMRV p53</td><td>XMRV p58</td></tr><tr><td>pVP62 (WT)</td><td>None</td><td>+</td><td>+</td></tr><tr><td>pVP62Δgg0</td><td>_ to A (nt 372)</td><td>-</td><td>-</td></tr><tr><td>pVP62Δgg1</td><td>C to AT (nt 382)</td><td>-</td><td>-</td></tr><tr><td>pVP62Δgg2</td><td>T to... | <table><tr><td>pVP62Δgg4</td><td>T to G (nt 354)</td><td>-</td><td>+</td></tr></table> |
c6184f15daa3913f151c7da6ad8f876cd55d8a91fda1d96172b3b65e7be2dbbf.png | simple | <table><tr><td>Observed</td><td>Poisson</td><td>Neg. Bin</td><td>ZIP</td><td>ZINB</td><td>PLH</td><td>NBLH</td></tr><tr><td>1705</td><td>183</td><td>1704</td><td>1705</td><td>1705</td><td>1705</td><td>1705</td></tr></table> | <table><tr><td>Observed</td><td>Poisson</td><td>Neg. Bin</td><td>ZIP</td><td>ZINB</td><td>PLH</td><td>NBLH</td></tr></table> | <table><tr><td>1705</td><td>183</td><td>1704</td><td>1705</td><td>1705</td><td>1705</td><td>1705</td></tr></table> |
46bade67bb528150efd62632cfa155a4bbf42ab14f33762233cbf90940582950.png | complex | <table><tr><td rowspan="2">HAZ or HAZ Difference</td><td colspan="2">Boys</td><td colspan="2">Girls</td></tr><tr><td>FPC1 Score <sup>b</sup></td><td>Adj-FPC2 Score<sup>c</sup></td><td>FPC1 Score<sup>b</sup></td><td>Adj-FPC2 Score<sup>c</sup></td></tr><tr><td> HAZ at enrollment</td><td>−0.849</td><td>0.292</td><td... | <table><tr><td rowspan="2">HAZ or HAZ Difference</td><td colspan="2">Boys</td><td colspan="2">Girls</td></tr><tr><td>FPC1 Score b</td><td>Adj-FPC2 Scorec</td><td>FPC1 Scoreb</td><td>Adj-FPC2 Scorec</td></tr><tr><td>HAZ at enrollment</td><td>−0.849</td><td>0.292</td><td>−0.971</td><td>−0.136d</td></tr><tr><td>HAZ at 6 m... | <table><tr><td rowspan="2">HAZ or HAZ Difference</td><td colspan="2">Boys</td><td colspan="2">Girls</td></tr><tr><td>FPC1 Score b</td><td>Adj-FPC2 Scorec</td><td>FPC1 Scoreb</td><td>Adj-FPC2 Scorec</td></tr><tr><td>HAZ at 24 months</td><td>−0.979</td><td>−0.425</td><td>−0.990</td><td>−0.467</td></tr><tr><td>Change of H... |
9b56e83cdad4f4f700a5e853edd83f1cd01088abb2d1e2a1624ff98e83623bb0.png | complex | <table><tr><td>Oil</td><td>Soybean oil</td><td>Soybean oil</td><td>Soybean oil</td><td>Salmon oil</td><td>Salmon oil</td><td>Salmon oil</td><td colspan="3">ANOVA (P)</td></tr><tr><td>Vitamin E (mg/kg)</td><td>25</td><td>250</td><td>2500</td><td>25</td><td>250</td><td>2500</td><td>Vitamin E</td><td>Oil</td><td>Vitamin E... | <table><tr><td>Oil</td><td>Soybean oil</td><td>Soybean oil</td><td>Soybean oil</td><td>Salmon oil</td><td>Salmon oil</td><td>Salmon oil</td><td colspan="3">ANOVA (P)</td></tr><tr><td>Vitamin E (mg/kg)</td><td>25</td><td>250</td><td>2500</td><td>25</td><td>250</td><td>2500</td><td>Vitamin E</td><td>Oil</td><td>Vitamin E... | <table><tr><td>g/d)</td><td>1.3</td><td>6 ± 1.4</td><td> ± 1.3</td><td>0.9</td><td>5</td><td> ± 1.7</td><td>.82</td><td></td><td>8</td></tr><tr><td>Feed/gain ratio (g/g)</td><td>5.9 ± 1.6</td><td>5.5 ± 0.5</td><td>5.7 ± 0.7</td><td>5.5 ± 0.6</td><td>5.5 ± 0.5</td><td>5.4 ± 0.4</td><td>0.71</td><td>0.25</td><td>0.60</td... |
d9afa80d5f2f6d5e1273b7e83052358d5870de4aa7d355b5d324926a5f53910a.png | complex | <table><tr><td></td><td>Maternal support</td><td>Paternal support</td></tr><tr><td colspan="3">Physical activity</td></tr><tr><td>All children</td><td>0.37**</td><td>0.36**</td></tr><tr><td>Boys</td><td>0.31**</td><td>0.26*</td></tr><tr><td>Girls</td><td>0.45**</td><td>0.45**</td></tr><tr><td colspan="3">Fruit and vege... | <table><tr><td></td><td>Maternal support</td><td>Paternal support</td></tr><tr><td colspan="3">Physical activity</td></tr><tr><td>All children</td><td>0.37**</td><td>0.36**</td></tr><tr><td>Boys</td><td>0.31**</td><td>0.26*</td></tr><tr><td>Girls</td><td>0.45**</td><td>0.45**</td></tr><tr><td colspan="3">Fruit and vege... | <table><tr><td>Girls</td><td>0.46**</td><td>0.05</td></tr></table> |
95ee3f0cd914a46e1b9828b936b9e0cff4e1c546f7e975f2a9d9d7efe0a70c68.png | simple | <table><tr><td>Patients</td><td>Uniform orthogonal grid</td><td>Uniform tetrahedron mesh</td><td>Nonuniform tetrahedron mesh</td></tr><tr><td>H&N01</td><td> </td><td> </td><td> </td></tr><tr><td> Number of vertices</td><td>936</td><td>992</td><td>1,007</td></tr><tr><td> NCC</td><td>0.8327</td><td>0.8358</td><td>0.8... | <table><tr><td>Patients</td></tr><tr><td>H&N01</td></tr><tr><td>Number of vertices</td></tr><tr><td>NCC</td></tr><tr><td>NRMSE</td></tr><tr><td>H&N02</td></tr><tr><td>Number of vertices</td></tr><tr><td>NCC</td></tr><tr><td>NRMSE</td></tr><tr><td>H&N03</td></tr><tr><td>Number of vertices</td></tr><tr><td>NCC</td></tr><... | <table><tr><td>Uniform orthogonal grid</td><td>Uniform tetrahedron mesh</td><td>Nonuniform tetrahedron mesh</td></tr><tr><td></td><td></td><td></td></tr><tr><td>936</td><td>992</td><td>1,007</td></tr><tr><td>0.8327</td><td>0.8358</td><td>0.8460</td></tr><tr><td>0.4988</td><td>0.4938</td><td>0.4792</td></tr><tr><td></td... |
9c67059b6466e6a9637f2756b846967431234806b5aac851df58855088ea36a0.png | complex | <table><tr><td> </td><td colspan="2">Kessounou South</td><td colspan="2">Malanville North</td><td colspan="2">Allada South</td><td colspan="2">Kandi North</td></tr><tr><td>Distance to water for washing nets</td><td colspan="4">< 0.05 km</td><td colspan="4">> 5.0 km</td></tr><tr><td>Assessment visit</td><td>T12</t... | <table><tr><td></td><td colspan="2">Kessounou South</td><td colspan="2">Malanville North</td><td colspan="2">Allada South</td><td colspan="2">Kandi North</td></tr><tr><td>Distance to water for washing nets</td><td colspan="4">< 0.05 km</td><td colspan="4">> 5.0 km</td></tr></table> | <table><tr><td></td><td colspan="2">Kessounou South</td><td colspan="2">Malanville North</td><td colspan="2">Allada South</td><td colspan="2">Kandi North</td></tr><tr><td>Assessment visit</td><td>T12</td><td>T18</td><td>T12</td><td>T18</td><td>T12</td><td>T18</td><td>T12</td><td>T18</td></tr><tr><td>n of nets found wit... |
2ad8a417c99a96cd61fbaa1f5c8b6a367fc8a80c5a717dac64cea2a718219cd1.png | simple | <table><tr><td></td><td>Standard method</td><td>Locally-based method</td><td>Total</td></tr><tr><td>Period of facility assessments</td><td>March-April, 2010</td><td>July-August, 2010</td><td>March-August, 2010</td></tr><tr><td>Number of survey teams used</td><td>1</td><td>24</td><td>25</td></tr><tr><td>All unique facil... | <table><tr><td></td><td>Standard method</td><td>Locally-based method</td><td>Total</td></tr><tr><td>Period of facility assessments</td><td>March-April, 2010</td><td>July-August, 2010</td><td>March-August, 2010</td></tr><tr><td>Number of survey teams used</td><td>1</td><td>24</td><td>25</td></tr><tr><td>All unique fac</... | <table><tr><td></td><td>Standard method</td><td>Locally-based method</td><td>Total</td></tr><tr><td>ilities assessed</td><td>1</td><td></td><td>4</td></tr><tr><td>Sub-Health Center</td><td>2</td><td>6</td><td>6</td></tr><tr><td>Basic Health Centers</td><td>8</td><td>16</td><td>16</td></tr><tr><td>Comprehensive Health C... |
868abefdd12914208dd07c68bb3ab9e4d4928b88bf7fb8dc06aec0f26ad4da94.png | simple | <table><tr><td>Category</td><td>AML with inv(16) (n = 27)</td><td>AMML without inv(16) * (n = 10)</td><td>Other types of AML * (n = 22)</td></tr><tr><td>Strong</td><td>20</td><td>1</td><td>7</td></tr><tr><td>Weak/Focal</td><td>5</td><td>3</td><td>3</td></tr><tr><td>Negative</td><td>2</td><td>6</td><td>12</td></tr></tab... | <table><tr><td>Category</td><td>AML with inv(16) (n = 27)</td><td>AMML without inv(16) * (n = 10)</td><td>Other types of AML * (n = 22)</td></tr><tr><td>Strong</td><td>20</td><td>1</td><td>7</td></tr><tr><td>Weak/Focal</td><td>5</td><td>3</td><td>3</td></tr></table> | <table><tr><td>Negative</td><td>2</td><td>6</td><td>12</td></tr></table> |
e93e1e9fcb24d89c160761ca181de5fae89c90c218e2aee494c8b141d068f087.png | complex | <table><tr><td><i>Age (years)</i></td><td colspan="2"><i>Male</i></td><td colspan="2"><i>Female</i></td></tr><tr><td> </td><td>n</td><td><i>%</i></td><td>n</td><td><i>%</i></td></tr><tr><td>7</td><td>4</td><td>40</td><td>4</td><td>40</td></tr><tr><td>8</td><td>6</td><td>60</td><td>3</td><td>30</td></tr><tr><td>9</td><t... | <table><tr><td>Age (years)</td><td colspan="2">Male</td><td colspan="2">Female</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>7</td><td>4</td><td>40</td><td>4</td><td>40</td></tr><tr><td>8</td><td>6</td><td>60</td><td>3</td><td>30</td></tr><tr><td>9</td><td>0</td><td>0</td><td>3</td><td>30</... | <table><tr><td>Total</td><td>10</td><td>100</td><td>10</td><td>100</td></tr></table> |
b3e442effc5d3848daf9db06a44b4c702adfdc771bc6756f699bc2b50b2dfe14.png | complex | <table><tr><td></td><td colspan="2"><i>RQCD1</i> mutant</td><td colspan="5"><i>RQCD1</i> WT</td></tr><tr><td>Mutation</td><td>n</td><td>%</td><td>n</td><td>%</td><td>OR</td><td>95%CI</td><td><i>p</i>-value</td></tr><tr><td><i>BRAF</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WT</t... | <table><tr><td></td><td colspan="2">RQCD1 mutant</td><td colspan="3">RQCD1 WT</td></tr><tr><td>Mutation</td><td>n</td><td>%</td><td>n</td><td>%</td><td>OR</td></tr><tr><td>BRAF</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>WT</td><td>17</td><td>59</td><td>448</td><td>65</td><td>1</td></tr><tr><td>V600E<... | <table><tr><td colspan="2">RQCD1 WT</td></tr><tr><td>95%CI</td><td>p-value</td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td>0.4, 2.3</td><td>0.9</td></tr><tr><td>1.1, 8.5</td><td>0.04</td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td>0.2, 2.5</td><td>0.6</td></tr></table> |
90a016de7d07bfa1666515cc65d9e820ca2d901145c0c3833bce798b55ec7552.png | simple | <table><tr><td>Fatty acids</td><td>CB diets</td><td>SF diets</td></tr><tr><td>Palmitic (16:0)</td><td>26.3</td><td>7.9</td></tr><tr><td>Palmitoleic (16:1)</td><td>0.2</td><td>0.1</td></tr><tr><td>Stearic (18:0)</td><td>29.0</td><td>2.3</td></tr><tr><td>Oleic (18:1n-9)</td><td>31.6</td><td>12.5</td></tr><tr><td>Linoleic... | <table><tr><td>Fatty acids</td><td>CB diets</td><td>SF diets</td></tr><tr><td>Palmitic (16:0)</td><td>26.3</td><td>7.9</td></tr><tr><td>Palmitoleic (16:1)</td><td>0.2</td><td>0.1</td></tr><tr><td>Stearic (18:0)</td><td>29.0</td><td>2.3</td></tr><tr><td>Oleic (18:1n-9)</td><td>31.6</td><td>12.5</td></tr><tr><td>Linoleic... | <table><tr><td>Fatty acids</td><td>CB diets</td><td>SF diets</td></tr><tr><td>PUFA/SFA ratio</td><td>0.21</td><td>7.14</td></tr><tr><td>n-6/n-3 ratio</td><td>8.8</td><td>68.5</td></tr><tr><td>Relative UI</td><td>0.57</td><td>1.67</td></tr></table> |
2e17c9658d91f94b80bb6c9f2f141b89dd451420de68a5d7c2388fbbd69c6c11.png | simple | <table><tr><td>Variable</td><td>Hazards ratio</td><td>95% CI*</td><td><i>P</i> value</td></tr><tr><td>Age (>45.89 vs. ≤45.89)</td><td>3.14</td><td>1.58–6.25</td><td>0.001</td></tr><tr><td>Clinical stage (III-IV vs. I-II)</td><td>3.27</td><td>1.00–10.67</td><td>0.050</td></tr><tr><td>Relapse (Yes vs... | <table><tr><td>Variable</td><td>Hazards ratio</td><td>95% CI*</td><td>P value</td></tr><tr><td>Age (>45.89 vs. ≤45.89)</td><td>3.14</td><td>1.58–6.25</td><td>0.001</td></tr><tr><td>Clinical stage (III-IV vs. I-II)</td><td>3.27</td><td>1.00–10.67</td><td>0.050</td></tr></table> | <table><tr><td>Relapse (Yes vs. No)</td><td>5.97</td><td>3.10–11.49</td><td>0.000</td></tr><tr><td>p53R2 expression (High vs. Low)</td><td>0.39</td><td>0.18–0.85</td><td>0.018</td></tr></table> |
df5c499ad8911c2841118b0a5036479cc18663351cd4bbdd910c215def0cf34b.png | complex | <table><tr><td></td><td>Number of patients (%) (<i>N</i> = 36)</td></tr><tr><td colspan="2">Age</td></tr><tr><td> Median (range)</td><td>58 (21–74)</td></tr><tr><td>≥ 65 years</td><td>10 (27.8%)</td></tr><tr><td colspan="2">Sex</td></tr><tr><td> Male</td><td>33 (91.7%)</td></tr><tr><td> Female</td><td>3 (8.... | <table><tr><td></td><td>Number of patients (%) (N = 36)</td></tr></table> | <table><tr><td colspan="2">Age</td></tr><tr><td>Median (range)</td><td>58 (21–74)</td></tr><tr><td>≥ 65 years</td><td>10 (27.8%)</td></tr><tr><td colspan="2">Sex</td></tr><tr><td>Male</td><td>33 (91.7%)</td></tr><tr><td>Female</td><td>3 (8.3%)</td></tr><tr><td colspan="2">Hepatocellular carcinoma etiology</td></tr><tr>... |
8b46ee8a85a812465ddd4d2cc47315d5fe4dab703ad059fce6a671bbe08b6a69.png | complex | <table><tr><td>Name</td><td><i>P</i>-value</td><td>Number of molecules</td></tr><tr><td colspan="3">Molecular and Cellular Functions</td></tr><tr><td>Cell Death and Survival</td><td>2.53 × 10<sup>−24</sup> to 1.36 × 10<sup>−3</sup></td><td>405</td></tr><tr><td>Cellular Growth and Proliferation</td... | <table><tr><td>Name</td><td>P-value</td><td>Number of molecules</td></tr><tr><td colspan="3">Molecular and Cellular Functions</td></tr><tr><td>Cell Death and Su</td><td>2.53 × 10−24 to 1.36 × 1</td><td>405</td></tr></table> | <table><tr><td>Name</td><td>P-value</td><td>Number of molecules</td></tr><tr><td>rvival</td><td>0−3</td><td></td></tr><tr><td>Cellular Growth and Proliferation</td><td>3.37 × 10−24 to 1.36 × 10−3</td><td>414</td></tr><tr><td>Cellular Movement</td><td>5.41 × 10−13 to 1.36 × 10−3</td><td>236</td></tr><tr><td>Gene Express... |
26b46a7a8a5b335885b29fe47aca977bb7e6eca92c9e9c2de45cce3046fddb22.png | simple | <table><tr><td>Confinement</td><td>CNVR</td><td>VMR</td><td>Total</td></tr><tr><td>Free Roaming</td><td>1441</td><td>4812</td><td>6253</td></tr><tr><td>Presented by owner</td><td>20</td><td>631</td><td>651</td></tr><tr><td>Total</td><td>1461</td><td>5443</td><td>6904</td></tr></table> | <table><tr><td>Confinement</td><td>CNVR</td><td>VMR</td><td>Total</td></tr><tr><td>Free Roaming</td><td>1441</td><td>4812</td><td>6253</td></tr><tr><td>Presented by owner</td><td>20</td><td>631</td><td>651</td></tr></table> | <table><tr><td>Confinement</td><td>CNVR</td><td>VMR</td><td>Total</td></tr><tr><td>Total</td><td>1461</td><td>5443</td><td>6904</td></tr></table> |
95482bca05ce3eaed84abe6d216968d37abafda74ce8b0069d2f0491f6bcb8be.png | simple | <table><tr><td>Database</td><td># Of Genes in Database</td><td>Last Updated <sup>1</sup></td><td>Database Source</td></tr><tr><td>ShortBRED VF <sup>2</sup></td><td>26,187</td><td>July 2017</td><td>https://huttenhower.sph.harvard.edu/shortbred</td></tr><tr><td>ShortBRED AR <sup>3</sup></td><td>932</td><td>July 2017</td>... | <table><tr><td>Database</td><td># Of Genes in Database</td><td>Last Updated 1</td><td>Database Source</td></tr><tr><td>ShortBRED VF 2</td><td>26,187</td><td>July 2017</td><td>https://huttenhower.sph.harvard.edu/shortbred</td></tr><tr><td>Sho</td><td>932</td><td>Ju</td><td>https://huttenhower.sph.</td></tr></table> | <table><tr><td>Database</td><td># Of Genes in Database</td><td>Last Updated 1</td><td>Database Source</td></tr><tr><td>rtBRED AR 3</td><td></td><td>ly 2017</td><td>harvard.edu/shortbred</td></tr><tr><td>Virulence Factor DataBase (VFDB)</td><td>30,246</td><td>February 2018</td><td>http://www.mgc.ac.cn/VFs/main.htm</td><... |
6fa49408dcb50095cb6036ff676cd110697f3dc0f5f7e2334f71683a22e6c920.png | simple | <table><tr><td>No.</td><td>Antibiotic</td><td>Abbr.</td><td>Concentration (μg)</td><td>Class</td></tr><tr><td>1.</td><td>Amikacin</td><td>AK</td><td>30</td><td>Aminoglycosides</td></tr><tr><td>2.</td><td>Amoxicillin/clavulanic acid<sup>a</sup></td><td>AMC</td><td>30</td><td>3rd generation penicillins</td></tr><tr>... | <table><tr><td>No.</td><td>Antibiotic</td><td>Abbr.</td><td>Concentration (μg)</td><td>Class</td></tr><tr><td>1.</td><td>Amikacin</td><td>AK</td><td>30</td><td>Aminoglycosides</td></tr><tr><td>2.</td><td>Amoxicillin/clavulanic acida</td><td>AMC</td><td>30</td><td>3rd generation penicillins</td></tr><tr><td>3.</td><td>A... | <table><tr><td>12.</td><td>cin</td><td></td><td></td><td>olons</td></tr><tr><td>13.</td><td>Gentamicin</td><td>CN</td><td>10</td><td>Aminoglycosides</td></tr><tr><td>14.</td><td>Netilmicin</td><td>NET</td><td>30</td><td>Aminoglycosides</td></tr><tr><td>15.</td><td>Piperacillin</td><td>PRL</td><td>100</td><td>4th genera... |
479c42f5ebf52b3f77a00f616f5313897c96bde31052cdb8f4f7824a75091b6f.png | simple | <table><tr><td>Variable</td><td>Diabetes case ascertainment cohort <i>n </i>(%)</td><td>Comorbidity case ascertainment cohort <i>n </i>(%)</td></tr><tr><td>Age group</td><td> </td><td> </td></tr><tr><td> < 65 years</td><td>1518 (6.5)</td><td>300 (7.2)</td></tr><tr><td> 65 – 74 years</td><td>2090 (9.0)</td><td>... | <table><tr><td>Variable</td><td>Diabetes case ascertainment cohort n (%)</td><td>Comorbidity case ascertainment cohort n (%)</td></tr></table> | <table><tr><td>Age group</td><td></td><td></td></tr><tr><td>< 65 years</td><td>1518 (6.5)</td><td>300 (7.2)</td></tr><tr><td>65 – 74 years</td><td>2090 (9.0)</td><td>554 (13.2)</td></tr><tr><td>75 – 84 years</td><td>7187 (31.0)</td><td>1517 (36.3)</td></tr><tr><td>85+ years</td><td>12422 (53.5)</td><td>1812 (43.3)</td>... |
f77a63c3b0d8a2bf63d24dcced3c5e54b554250206fe6ce901315bda016cc760.png | simple | <table><tr><td>Stakeholders’ designation</td><td>Number of participants</td></tr><tr><td>Mobile phone programming company</td><td>1</td></tr><tr><td>Clinicians</td><td>4</td></tr><tr><td>Community health workers</td><td>4</td></tr><tr><td>Research team</td><td>4</td></tr><tr><td>District health management teams</... | <table><tr><td>Stakeholders’ designation</td><td>Number of participants</td></tr><tr><td>Mobile phone programming company</td><td>1</td></tr></table> | <table><tr><td>Clinicians</td><td>4</td></tr><tr><td>Community health workers</td><td>4</td></tr><tr><td>Research team</td><td>4</td></tr><tr><td>District health management teams</td><td>10</td></tr><tr><td>Total</td><td>23</td></tr></table> |
c6e1ae86fc6e6cf096456612a078c07da75e430299d1c19b3eb8328b74bb0a30.png | complex | <table><tr><td>CHP per subject</td><td colspan="2">Number of subjects (%)</td><td>Number of conditions</td><td>CHP/subj average</td><td>Column-%</td></tr><tr><td>0 = MM0</td><td>17,273</td><td>(19.7)</td><td>0</td><td>0</td><td>0</td></tr><tr><td>1 = MM1</td><td>14,328</td><td>(16.3)</td><td>14,328</td><td>1</td><td>4.... | <table><tr><td>CHP per subject</td><td colspan="2">Number of subjects (%)</td><td>Number of conditions</td></tr><tr><td>0 = MM0</td><td>17,273</td><td>(19.7)</td><td>0</td></tr><tr><td>1 = MM1</td><td>14,328</td><td>(16.3)</td><td>14,328</td></tr><tr><td>2 = MM2</td><td>12,762</td><td>(14.5)</td><td>25,524</td></tr><tr... | <table><tr><td>CHP/subj average</td><td>Column-%</td></tr><tr><td>0</td><td>0</td></tr><tr><td>1</td><td>4.7</td></tr><tr><td>2</td><td>8.4</td></tr><tr><td>3</td><td>10.3</td></tr><tr><td>4.4</td><td>20.8</td></tr><tr><td>7.5</td><td>35.4</td></tr><tr><td>13.5</td><td>20.4</td></tr><tr><td>3.4</td><td>100</td></tr></t... |
08781ab6abdc97264bd333d6354ae75b08b0f3189dec7e6e82087cc1cb805b0d.png | complex | <table><tr><td>N = 3520</td><td>Total number of women</td><td>%</td><td>95% CIs</td></tr><tr><td colspan="4">Given information during pregnancy (Told about pregnancy complications or told where to go for pregnancy complications or advised to use a skilled birth attendant)</td></tr><tr><td>Yes</td><td>2,872</td><td>81.6... | <table><tr><td>N = 3520</td><td>Total number of women</td></tr><tr><td colspan="2">Given information during pregnancy (Told about pregnancy complications or told where to go for pregnancy complications or advised to use a skilled birth attendant)</td></tr><tr><td>Yes</td><td>2,872</td></tr><tr><td colspan="2">Iron tabl... | <table><tr><td>%</td><td>95% CIs</td></tr><tr><td colspan="2">Given information during pregnancy (Told about pregnancy complications or told where to go for pregnancy complications or advised to use a skilled birth attendant)</td></tr><tr><td>81.6</td><td>78.5 to 84.4</td></tr><tr><td colspan="2">Iron tablets/syrup tak... |
9f3a03c8965884bddc11556d02c2e1814f761565b27f6cbcc2faf94e55c5a955.png | simple | <table><tr><td>Early events in the disease course</td><td>EDSS outcome in patients with long term follow-up (≥ 100 months)(median, range; N)</td><td>p-level</td></tr><tr><td>Motor symptoms at first myelitis*Sensory symptoms at first myelitis*</td><td>7 (1.5-10; 29)5.25 (2-9; 16)</td><td>p < 0.04<sup>§</su... | <table><tr><td>Early events in the disease course</td><td>EDSS outcome in patients with long term follow-up (≥ 100 months)(median, range; N)</td><td>p-level</td></tr></table> | <table><tr><td>Motor symptoms at first myelitis*Sensory symptoms at first myelitis*</td><td>7 (1.5-10; 29)5.25 (2-9; 16)</td><td>p < 0.04§</td></tr><tr><td>Motor symptoms at onsetSensory symptoms at onset</td><td>8.25 (5.5-10; 8)4 (2-6.5; 5)</td><td>p < 0.007§</td></tr><tr><td>Tetraparesis at first myelitis*Motor sympt... |
6981022024a9003a4ae09730022dd108655f4f232f0dab9d6cc6ac6bdeba2bcd.png | simple | <table><tr><td></td><td>18S+28S vs. 18S+28S</td><td>18S+28S vs. cox1+cox3</td><td>18S+28S vs. tufA</td><td>cox1+cox3 vs. 18S+28S</td><td>cox1+cox3 vs. cox1+cox3</td><td>cox1+cox3 vs. tufA</td><td>tufA vs. 18S+28S</td><td>tufA vs. cox1+cox3</td><td>tufA vs. tufA</td></tr><tr><td>BP</td><td>0.989</td><td>0</td><td>0</td>... | <table><tr><td></td><td>18S+28S vs. 18S+28S</td><td>18S+28S vs. cox1+cox3</td><td>18S+28S vs. tufA</td><td>cox1+cox3 vs. 18S+28S</td><td>cox1+cox3 vs. cox1+cox3</td><td>cox1+cox3 vs. tufA</td><td>tufA vs. 18S+28S</td><td>tufA vs. cox1+cox3</td><td>tufA vs. tufA</td></tr><tr><td>BP</td><td>0.989</td><td>0</td><td>0</td>... | <table><tr><td>AU</td><td>0.994</td><td>0</td><td>0</td><td>0</td><td>0.235</td><td>0</td><td>0</td><td>0</td><td>0.235</td></tr><tr><td>ln</td><td>−3114.161</td><td>−3217.96</td><td>−3192.395</td><td>−3213.426</td><td>−2301.843</td><td>−2819.113</td><td>−1822.457</td><td>−1667.534</td><td>−1259.645</td></tr></table> |
d6c68b971be9b7d31de745c9b5a2148bb3f2d128b1d94ebabb8dc32ee81b28bc.png | simple | <table><tr><td>Parameter</td><td>Estimate</td><td>SE</td><td><i>T</i></td><td><i>i</i></td></tr><tr><td>Intercept</td><td>0.974</td><td>0.261</td><td>3.736</td><td><0.001</td></tr><tr><td>Species</td><td>−2.028</td><td>0.369</td><td>−5.500</td><td><0.001</td></tr><tr><td>Acc.Temp</td><td>−0.057<... | <table><tr><td>Parameter</td><td>Estimate</td><td>SE</td><td>T</td><td>i</td></tr><tr><td>Intercept</td><td>0.974</td><td>0.261</td><td>3.736</td><td><0.001</td></tr><tr><td>Species</td><td>−2.028</td><td>0.369</td><td>−5.500</td><td><0.001</td></tr><tr><td>Acc.Temp</td><td>−0.057</td><td>0.018</td><td>−3.231</td><td>0... | <table><tr><td>pecies × Acc.Temp</td><td></td><td>5</td><td>9</td><td>1</td></tr></table> |
da88215a3e8b18af164e755202b29ec19b77a8d986eb92fcc31f2c09b17e4cf2.png | complex | <table><tr><td rowspan="2">Toxicity</td><td colspan="5">Number of Patients Reporting Toxicity by Grade<sup>a</sup>(<i>N</i> = 24 total toxicities)</td><td rowspan="2">Total</td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr><tr><td>Pain</td><td>2</td><td>7</td><td>0</td><td>0</td><td>0</td><td>9</td></... | <table><tr><td rowspan="2">Toxicity</td><td colspan="5">Number of Patients Reporting Toxicity by Gradea(N = 24 total toxicities)</td><td rowspan="2">Total</td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr><tr><td>Pain</td><td>2</td><td>7</td><td>0</td><td>0</td><td>0</td><td>9</td></tr><tr><td>F</td><... | <table><tr><td rowspan="2">Toxicity</td><td colspan="5">Number of Patients Reporting Toxicity by Gradea(N = 24 total toxicities)</td><td rowspan="2">Total</td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr><tr><td>atigue</td><td>2</td><td></td><td>0</td><td></td><td>0</td><td>2</td></tr><tr><td>Pneumon... |
cfac757d462ad7643c357bad3964e9555e68b1e0887adddc972d9bb5e9a6e259.png | complex | <table><tr><td colspan="2">Variables (Percentage)</td></tr><tr><td>No. patients</td><td>74</td></tr><tr><td>Age (years)</td><td></td></tr><tr><td> Mean</td><td>59.8 ± 15.6</td></tr><tr><td> Median</td><td>62</td></tr><tr><td>Sex (female/male)</td><td>53/47</td></tr><tr><td>Mechanically ventilated</td><td>84</td></... | <table><tr><td colspan="2">Variables (Percentage)</td></tr><tr><td>No. patients</td><td>74</td></tr><tr><td>Age (years)</td><td></td></tr><tr><td>Mean</td><td>59.8 ± 15.6</td></tr><tr><td>Median</td><td>62</td></tr></table> | <table><tr><td>Sex (female/male)</td><td>53/47</td></tr><tr><td>Mechanically ventilated</td><td>84</td></tr><tr><td>Oxygen by</td><td></td></tr><tr><td>Mask</td><td>9</td></tr><tr><td>Nasal tube</td><td>7</td></tr><tr><td>Central venous line</td><td>76</td></tr><tr><td>Intra-arterial catheter</td><td>92</td></tr><tr><t... |
f11fe335754458027d7fbe7ec0a257d2b8f893ab209b638d0623909cf1724713.png | simple | <table><tr><td></td><td>IQ</td><td>Working memory</td><td>Inhibitory control</td><td>Emotion recognition</td></tr><tr><td>Working memory</td><td>.39</td><td></td><td></td><td></td></tr><tr><td>Inhibitory control</td><td>.21</td><td>.11</td><td></td><td></td></tr><tr><td>Emotion recognition</td><td>−.16</td><td>&#... | <table><tr><td></td><td>IQ</td><td>Working memory</td><td>Inhibitory control</td></tr><tr><td>Working memory</td><td>.39</td><td></td><td></td></tr><tr><td>Inhibitory control</td><td>.21</td><td>.11</td><td></td></tr><tr><td>Emotion recognition</td><td>−.16</td><td>−.11</td><td>−.09</td></tr><tr><td>ADHD hyperactive-im... | <table><tr><td>Emotion recognition</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>.09</td></tr><tr><td>.09</td></tr><tr><td>.10</td></tr><tr><td>.08</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.